MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Cardiovascular Drugs and Therapy' source. Wed, 08 Feb 2012 09:32:32 +0100 http://www.medworm.com/index.php?rid=5666990&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F138u6303g6q51x17%2F Conclusions  In CandHeart, the addition of candesartan to standard medical treatment did not reduce circulating BNP more than standard therapy (primary endpoint), but it significantly improved LV function and produced a marked decrease in aldosterone levels at study end. Content Type Journal ArticlePages 1-13DOI 10.1007/s10557-012-6370-8Authors Aneta Aleksova, Cardiovascular Department, “Ospedali Riuniti” and University of Trieste, Trieste, ItalySerge Masson, Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche “Mario Negri”, via Giuseppe La Masa 19, 20156 Milan, ItalyAldo P. Maggioni, ANMCO Research Center, Florence, ItalyDonata Lucci, ANMCO Research Center, Florence, ItalyRenato Urso, ANMCO Research Center, Florence, ItalyLidia Staszew... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5666990 Thu, 02 Feb 2012 18:16:26 +0100 5666990 http://www.medworm.com/index.php?rid=5638316&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk7u854383g536811%2F Conclusions  Fenofibrate blunts IL-1β-mediated ENA-78 production with no effect on IL-8. This represents a novel mechanism by which fenofibrate exerts anti-inflammatory effects and should be further explored. Content Type Journal ArticlePages 1-5DOI 10.1007/s10557-011-6368-7Authors Elvin Tyrone Price, University of Arkansas for Medical Sciences, Little Rock, AR, USAGregory James Welder, Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USAIssam Zineh, Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5638316 Tue, 24 Jan 2012 12:27:21 +0100 5638316 http://www.medworm.com/index.php?rid=5597173&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6036344lp45n6013%2F Conclusions  There is an urgent need to successfully control hypertension in the black population. Although data are limited in blacks, evidence suggests that central blood pressure warrants more continued assessment in future clinical studies. Content Type Journal ArticleCategory Review ArticlePages 1-9DOI 10.1007/s10557-011-6367-8Authors Keith C. Ferdinand, Division of Cardiology, Tulane University School of Medicine and Association of Black Cardiologists, Inc., 1430 Tulane Ave, SL-48, New Orleans, LA 70112, USARaymond R. Townsend, University of Pennsylvania, Philadelphia, PA, USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5597173 Fri, 13 Jan 2012 16:48:36 +0100 5597173 http://www.medworm.com/index.php?rid=5597174&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw8041021991q7l56%2F Content Type Journal ArticleCategory ISCP President's LetterPages 1-2DOI 10.1007/s10557-011-6369-6Authors Juan-Carlos Kaski, St. George’s, University of London, London, United Kingdom Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5597174 Fri, 13 Jan 2012 16:48:35 +0100 5597174 http://www.medworm.com/index.php?rid=5559754&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3n0441368u7t3q65%2F Conclusions  In the porcine heart, both RIPC and RIPerC both reduce myocardial infarct size and with RIPC but not RIPerC this cardioprotective effect is associated with the activation of the PI3K-Akt pathway at reperfusion. Content Type Journal ArticlePages 1-7DOI 10.1007/s10557-011-6364-yAuthors D. J. Hausenloy, The Hatter Cardiovascular Institute, University College London Hospital & Medical School, London, UKE. K. Iliodromitis, 2nd University Department of Cardiology, Attikon General Hospital, Medical School, University of Athens, Athens, GreeceI. Andreadou, Department of Pharmaceutical Chemistry, School of Pharmacy, University of Athens, Athens, GreeceA. Papalois, 2nd University Department of Cardiology, Attikon General Hospital, Medical School, University of Athe... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5559754 Fri, 30 Dec 2011 07:08:58 +0100 5559754 http://www.medworm.com/index.php?rid=5537564&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk454014323713m24%2F Conclusion  PMQ has significant protective effects on cardiac hypertrophy through up-regulating the mRNA and protein levels of PPAR α and PPAR β involved in the process of inflammation response and cardiac fibrosis. Content Type Journal ArticlePages 1-12DOI 10.1007/s10557-011-6363-zAuthors Ting He, Department of Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaLei Chen, Department of Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaYong Chen, Department of Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaYi Han, Department of Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaWei... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5537564 Tue, 20 Dec 2011 06:43:32 +0100 5537564 http://www.medworm.com/index.php?rid=5515264&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F07j35g73uk240k23%2F Conclusions  MSCs play an immunomodulatory paracrine role when injected in rats submitted to carotid arteriotomy, accompanied by the release of VEGF, possibly contributing to the accelerated repair of the injured vascular wall. Content Type Journal ArticlePages 1-13DOI 10.1007/s10557-011-6359-8Authors Amalia Forte, Department of Experimental Medicine, Second University of Naples, Via L. De Crecchio, 7-80138 Naples, ItalyBarbara Rinaldi, Department of Experimental Medicine, Second University of Naples, Via L. De Crecchio, 7-80138 Naples, ItalyLoredana Sodano, Department of Experimental Medicine, Second University of Naples, Via L. De Crecchio, 7-80138 Naples, ItalyLiberato Berrino, Department of Experimental Medicine, Second University of Naples, Via L. De Crecchio, 7-... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5515264 Wed, 14 Dec 2011 06:57:38 +0100 5515264 http://www.medworm.com/index.php?rid=5504587&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F736182j101l48661%2F Content Type Journal ArticleCategory EDITORIALPages 1-3DOI 10.1007/s10557-011-6362-0Authors Peter J. Psaltis, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5504587 Mon, 12 Dec 2011 17:12:00 +0100 5504587 http://www.medworm.com/index.php?rid=5486645&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm885507200201765%2F Abstract  More than a century has passed since the renin-angiotensin-aldosterone system (RAAS) was discovered in 1897. Both circulatory and tissue RAAS have been found to be essential for regulation of the functions of the whole body, organs, tissues and cells. There is no doubt that the RAAS plays fundamental physiological roles in maintaining homeostasis, but it can also contribute to organ pathophysiology and tissue damages in some situations. Today, the usefulness of RAAS blockade is well-established in the management of a variety of cardiovascular disorders worldwide. However, the latest findings in this field are still providing us with new and unexpected insights into the pathophysiology of cardiovascular diseases. Such developments include dual blockade therapy with... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5486645 Tue, 06 Dec 2011 17:03:42 +0100 5486645 http://www.medworm.com/index.php?rid=5476320&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx32w1550m72825x5%2F Abstract  Nitric oxide donors have been commonly used in the therapy of cardiovascular disease for more than 150 years. In spite of this longevity and the popularity of their use, it appears somewhat paradoxical that there is no current consistent use among cardiologists, as to both their indications and their optimal mode of administration. In part this results from their contradictory pharmacodynamics: when given acutely, their effectiveness is undisputable; however, their long-term efficacy is potentially limited by the development of tolerance and the induction of endothelial dysfunction, which may have negative prognostic implications. This review reports recent biochemical and pathophysiological acquisitions, re-examines the role of nitrates and other nitric oxid... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5476320 Thu, 01 Dec 2011 19:29:53 +0100 5476320 http://www.medworm.com/index.php?rid=5449668&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1122987023g62n49%2F Abstract Purpose  To evaluate the pharmacokinetic profile of tolvaptan. Method  The nonclinical pharmacokinetic profile of [14C]tolvaptan was evaluated in an absorption, distribution, and excretion study in rats after single oral administration. An in vitro protein binding study was also performed. Results  The tolvaptan-derived radioactivity was rapidly absorbed and extensively distributed to all tissues in rats. The radioactivity levels were greatest in the gastrointestinal tract and liver, though the levels in the cerebrum, cerebellum and medulla oblongata were low. The serum and tissue concentrations of radioactivity, and serum concentration of tolvaptan in male and female rats showed a marked sex difference. The radioactivity was cros... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5449668 Fri, 25 Nov 2011 17:56:31 +0100 5449668 http://www.medworm.com/index.php?rid=5449669&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg01413146061k243%2F Conclusions  Once-daily tolvaptan (15, 30 or 45 mg) was effective and tolerable as an add-on treatment to furosemide therapy in Japanese HF patients with volume overload. Content Type Journal ArticlePages 1-13DOI 10.1007/s10557-011-6303-yAuthors Masunori Matsuzaki, Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, JapanMasatsugu Hori, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, JapanTohru Izumi, Department of Cardio-Angiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minamiku, Sagamihara, Kanagawa 252-0373, JapanHidetsugu Asanoi, Imizu City Hospital, Toyama, JapanTakayoshi Tsutamoto, Department of Cardiovascular and Respiratory Medicine, Shiga U... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5449669 Fri, 25 Nov 2011 17:56:30 +0100 5449669 http://www.medworm.com/index.php?rid=5449672&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7j8430476600677p%2F Conclusion  Tolvaptan exerts diuretic effects and causes body weight loss at the low dose of 7.5 mg; however, these effects were less than those elicited by 15 mg tolvaptan. Content Type Journal ArticlePages 1-9DOI 10.1007/s10557-011-6349-xAuthors Takayuki Inomata, Department of Cardio-Angiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minamiku, Sagamihara, Kanagawa, 252–0373, JapanTohru Izumi, Department of Cardio-Angiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minamiku, Sagamihara, Kanagawa, 252–0373, JapanMasunori Matsuzaki, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, JapanMasatsugu Hori, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japa... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5449672 Fri, 25 Nov 2011 17:56:29 +0100 5449672 http://www.medworm.com/index.php?rid=5449671&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp2586l642086466m%2F Conclusions  This study confirms the efficacy and safety of 15 mg/day tolvaptan for 7–14 days in Japanese HF patients with volume overload despite conventional diuretics. Content Type Journal ArticlePages 1-10DOI 10.1007/s10557-011-6348-yAuthors Masatake Fukunami, Cardiovascular Center, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558 JapanMasunori Matsuzaki, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, JapanMasatsugu Hori, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, JapanTohru Izumi, Department of Cardio-Angiology, Kitasato University School of Medicine, Sagamihara, Japanfor the Tolvaptan Investigators Journal Cardiovascular Drugs and Th... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5449671 Fri, 25 Nov 2011 17:56:29 +0100 5449671 http://www.medworm.com/index.php?rid=5449670&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fft8298674uw20q1r%2F Conclusion  Tolvaptan had anti-edematous effects in two different rat models. By increasing free water excretion, tolvaptan may be more advantageous for certain patients than loop diuretics because it does not cause electrolyte loss, and may prevent electrolyte abnormities, such as hyponatremia. These results suggest that tolvaptan has potential clinical benefits for the treatment of edema. Content Type Journal ArticlePages 1-6DOI 10.1007/s10557-011-6355-zAuthors Toshiki Miyazaki, First Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd, 463-10 Kagasuno, Kawauchi-cho, Tokushima, 771-0192 JapanYuki Sakamoto, First Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd, 463-10 Kagasuno, Kawauchi-cho, Tokushima, 771-0192 JapanTatsuya Yamashita, Fi... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5449670 Fri, 25 Nov 2011 17:56:29 +0100 5449670 http://www.medworm.com/index.php?rid=5449673&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn62q36309v7x1210%2F Conclusion  Tolvaptan elicited a potent aquaretic response and reduced the cardiac preload without unfavorable effects on systemic or renal hemodynamics, the renin–angiotensin–aldosterone system, or the sympathetic nervous system in CHF dogs. Thus, tolvaptan may offer a novel approach to remove excess water congestion from patients with CHF. Content Type Journal ArticlePages 1-10DOI 10.1007/s10557-011-6350-4Authors Toshiyuki Onogawa, First institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd, Tokushima, JapanYuki Sakamoto, First institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd, Tokushima, JapanShigeki Nakamura, First institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd, Tokushima, JapanSunao Nakayama, First institute of New Dr... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5449673 Fri, 25 Nov 2011 17:56:28 +0100 5449673 http://www.medworm.com/index.php?rid=5449674&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6t253772u1634wr2%2F Content Type Journal ArticleCategory ErratumPages 1-1DOI 10.1007/s10557-011-6360-2Authors Masatsugu Hori, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka, 537-8511 Japan Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5449674 Fri, 25 Nov 2011 17:56:27 +0100 5449674 http://www.medworm.com/index.php?rid=5449676&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv523l1415318q17k%2F Conclusions  Single and multiple oral doses of tolvaptan exhibited dose-dependent aquaretic effects. Tolvaptan was well tolerated at all doses tested. Content Type Journal ArticlePages 1-13DOI 10.1007/s10557-011-6299-3Authors Seong Ryul Kim, Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, 3-2-27 Otedori, Chuo-ku, Osaka, 540–0021 JapanTomoko Hasunuma, Kitasato University Research Center for Clinical Pharmacology, 5-9-1 Shirokane, Minato-ku, Tokyo, 108–8642 JapanOsamu Sato, Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, 3-2-27 Otedori, Chuo-ku, Osaka, 540–0021 JapanTadashi Okada, Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, 3-2-27 Otedori, Chuo-ku, Osaka, 540–0... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5449676 Fri, 25 Nov 2011 17:56:26 +0100 5449676 http://www.medworm.com/index.php?rid=5449675&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm32h2131g612762u%2F Conclusion  Tolvaptan reduced volume overload and improved congestive symptoms associated with HF by a potent water diuresis (aquaresis). Content Type Journal ArticlePages 1-13DOI 10.1007/s10557-011-6304-xAuthors Masunori Matsuzaki, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, JapanMasatsugu Hori, Osaka Medical Center for Cancer and Cardiovascular Disease, 1-3-3 Nakamichi, Higashinari-ku, Osaka, 537–8511 JapanTohru Izumi, Department of Cardio-Angiology, Kitasato University School of Medicine, Sagamihara, JapanMasatake Fukunami, Cardiovascular Center, Osaka General Medical Center, Osaka, Japanfor the Tolvaptan Investigators Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Sou... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5449675 Fri, 25 Nov 2011 17:56:26 +0100 5449675 http://www.medworm.com/index.php?rid=5449677&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Flk7j128169t1p667%2F Conclusion  Nonclinical toxicity that precludes the safe administration of tolvaptan to humans was not observed. However, appropriate cautions should be taken in women of childbearing potential. Content Type Journal ArticlePages 1-9DOI 10.1007/s10557-011-6356-yAuthors Akihide Oi, Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd, 463-10 Kagasuno, Kawauchi-cho, Tokushima, 771-0192 JapanKatsumi Morishita, Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd, 463-10 Kagasuno, Kawauchi-cho, Tokushima, 771-0192 JapanTakumi Awogi, Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd, 463-10 Kagasuno, Kawauchi-cho, Tokushima, 771-0192 JapanAtsushi Ozaki, Departme... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5449677 Fri, 25 Nov 2011 17:56:25 +0100 5449677 http://www.medworm.com/index.php?rid=5449678&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6t28g85342183u76%2F Conclusion  sPLA2 inhibition has the potential to exert a favorable effect on the artery wall. The VISTA-16 study will determine whether varespladib methyl has a beneficial impact on cardiovascular events in patients with an acute coronary syndrome. Content Type Journal ArticlePages 1-5DOI 10.1007/s10557-011-6358-9Authors Stephen J. Nicholls, Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USAMatthew A. Cavender, Department of Cardiovascular Medicine, Cleveland Clinic, Mail Code JJ-65, 9500, Euclid Avenue, Cleveland, OH 44195, USAJohn J. P. Kastelein, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsGregory Schwartz, VA Medical Center and University of Colorado Denver, De... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5449678 Wed, 23 Nov 2011 16:33:41 +0100 5449678 http://www.medworm.com/index.php?rid=5421834&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy565k4620152g1j0%2F Abstract  Endothelial dysfunction contributes to the initiation and development of hypertension. We previously found that simvastatin moderately decreases blood pressure in 2-kidney-2-clip (2k2c) renal hypertension, but the precise mechanisms are still unclear. The present study was designed to examine the protective actions of simvastatin in 2k2c-evoked endothelial dysfunction and also delineate the underlying mechanisms. Here we show that 2k2c-induced elevation in plasma angiotensin II impaired acetylcholine-induced endothelium-dependent vascular relaxation, suppressed endothelial NO synthase (eNOS) activity and reduced nitric oxide (NO) production. Additionally, the levels of tetrahydrobiopterin (BH4), an essential cofactor of eNOS, as well as the activity of GTP cyclohy... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5421834 Mon, 14 Nov 2011 16:52:44 +0100 5421834 http://www.medworm.com/index.php?rid=5407571&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F686574667u252741%2F Conclusion  PTC124 has no acute or long-term effects on rabbit ventricular action potentials. These experiments form the basis for future studies evaluating the use of this therapy in preventing potentially lethal arrhythmias in patients with BrS and/or conduction disease. Content Type Journal ArticlePages 1-5DOI 10.1007/s10557-011-6352-2Authors Tamara T. Koopmann, Heart Failure Research Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, The NetherlandsArie O. Verkerk, Heart Failure Research Center, Department of Anatomy, Embryology & Physiology, Academic Medical Center, Amsterdam, The NetherlandsConnie R. Bezzina, Heart Failure Research Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, A... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5407571 Tue, 08 Nov 2011 06:50:42 +0100 5407571 http://www.medworm.com/index.php?rid=5386028&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp861608g4863g167%2F Content Type Journal ArticleCategory EDITORIALPages 1-3DOI 10.1007/s10557-011-6353-1Authors Wei Kong, Department of Physiology and Pathophysiology, Peking University Health Sciences Center, Beijing, 100191 ChinaYi Zhu, Department of Physiology and Pathophysiology, Peking University Health Sciences Center, Beijing, 100191 China Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5386028 Fri, 04 Nov 2011 05:44:35 +0100 5386028 http://www.medworm.com/index.php?rid=5360205&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe285m0671p885255%2F Conclusion  In the present study, we show novel data to suggest that simvastatin could suppress apoptosis in vulnerable atherosclerotic plaques of apoE−/− mice by regulating the expression of apoptosis-related proteins, such as p53, Bcl-2 and Bcl-xL. Content Type Journal ArticlePages 1-8DOI 10.1007/s10557-011-6347-zAuthors Weiwei Qin, The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing, 100730 ChinaYonggang Lu, The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing, 100730 ChinaChengyan Zhan, Shanghai PuNan Hospital, Shanghai, 200125 ChinaTao Shen, The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5360205 Fri, 28 Oct 2011 17:25:00 +0100 5360205 http://www.medworm.com/index.php?rid=5335446&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv9280806g1765126%2F Conclusions  Currently there is no role for ARBs in secondary prevention of AF. With regard to ACEIs, the data are not strong enough for a conclusion, although the efficacy is expected to be the same as that of ARBs. Content Type Journal ArticleCategory Review ArticlePages 1-8DOI 10.1007/s10557-011-6346-0Authors Marcello Disertori, Department of Cardiology, Santa Chiara Hospital, Largo Medaglie d’Oro, 38122 Trento, ItalySimona Barlera, Department of Cardiovascular Research, Istituto Mario Negri, Milan, ItalyLidia Staszewsky, Department of Cardiovascular Research, Istituto Mario Negri, Milan, ItalyRoberto Latini, Department of Cardiovascular Research, Istituto Mario Negri, Milan, ItalySilvia Quintarelli, Department of Cardiology, Santa Chiara Hospital, Largo Medaglie... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5335446 Tue, 18 Oct 2011 15:57:29 +0100 5335446 http://www.medworm.com/index.php?rid=5335447&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu0k2661587114436%2F Content Type Journal ArticleCategory EditorialPages 1-2DOI 10.1007/s10557-011-6345-1Authors John McNeil, Department of Epidemiology & Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Alfred Centre, 99 Commercial Road, Melbourne, Victoria 3004, AustraliaAndrew Tonkin, Department of Epidemiology & Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Alfred Centre, 99 Commercial Road, Melbourne, Victoria 3004, Australia Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5335447 Mon, 17 Oct 2011 16:04:28 +0100 5335447 http://www.medworm.com/index.php?rid=5314226&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx2582142l7884w90%2F Abstract  Diabetes mellitus is a common metabolic disease characterized by a state of oxidative stress, inflammation and endothelial dysfunction. This malady can lead to a number of complications such as ischemic heart disease, nephropathy, neuropathy, retinopathy and impaired wound healing. The etiology of diabetic complications is multifactorial, and is closely associated with oxidative stress and inflammation. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), a receptor for oxidized low density lipoprotein (ox-LDL), plays critical roles in multiple signal transduction pathways and is involved in the process of oxidative stress and inflammation. Recent studies provide important insights into the roles of LOX-1 in the development and progression of diabetic ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5314226 Wed, 12 Oct 2011 16:04:59 +0100 5314226 http://www.medworm.com/index.php?rid=5314227&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe26702672327wn20%2F Conclusions  Varespladib significantly reduces the post-ACS inflammatory response in those with and without diabetes. These responses were greater in diabetic subjects compared to non-diabetic subjects. Content Type Journal ArticlePages 1-6DOI 10.1007/s10557-011-6344-2Authors Robert S. Rosenson, Mount Sinai School of Medicine, 1425 Madison Ave., New York, NY 10029, USAHeather Fraser, Anthera Pharmaceuticals, Inc., 25801 Industrial Blvd., Suite B, Hayward, CA 94545, USAMichael A. Goulder, Worldwide Clinical Trials, Isaac Newton Centre, Nottingham Science Park, Nottingham, UK NG7 2RHColin Hislop, Anthera Pharmaceuticals, Inc., 25801 Industrial Blvd., Suite B, Hayward, CA 94545, USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5314227 Tue, 11 Oct 2011 15:49:42 +0100 5314227 http://www.medworm.com/index.php?rid=5314228&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn2463um0047h56h1%2F Conclusions  AL, dose dependently limited myocardial IS in mice with type-2 diabetes mellitus. At doses shown to limit IS in non-diabetic animals, VA failed to reduce IS in Db/Db mice. However, at higher dose (16 mg/kg/d), VA reduced IS. Both drugs reduced the expression of AT1R and increased myocardial levels of the longevity genes Sirt1 and PGC-1α along with increased Akt and eNOS phosphorylation. Content Type Journal ArticlePages 1-11DOI 10.1007/s10557-011-6339-zAuthors Yumei Ye, The Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, MRB 5:108, 301 University Blvd., Galveston, TX 77555, USAJinqiao Qian, The Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, MRB 5:108, 301 University Blvd.... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5314228 Mon, 10 Oct 2011 15:01:15 +0100 5314228 http://www.medworm.com/index.php?rid=5296820&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe610326k85u34663%2F Abstract  Angiogenesis is defined as the formation of new blood vessels sprouting from pre-existing vessels. It plays an important role not only in physiological situations such as embryonic vascular development and wound healing, but also in pathological conditions including atherogenesis and evolution and spread of certain tumors. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), a receptor for oxidized low density lipoprotein (ox-LDL), is mainly expressed in endothelial cells. It has diverse physiological functions and it could be a link between atherogenesis and tumorigenesis. The risk factors for atherosclerosis like hypertension, diabetes mellitus and hyperlipidemia are associated with LOX-1. Dyslipidemia and obesity are also being recognized as risk fa... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5296820 Tue, 04 Oct 2011 05:49:09 +0100 5296820 http://www.medworm.com/index.php?rid=5273500&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Faw613h0748x55712%2F Abstract  An elevated level of low density lipoprotein (LDL) cholesterol constitutes a major risk factor for genesis of atherosclerosis. Ox-LDL plays a more important role in the genesis and progression of atherosclerosis than the native LDL. Ox-LDL leads to endothelial dysfunction leading to expression of adhesion molecules and recruitment of monocyte in subendothelial space. Ox-LDL is taken up by macrophages via scavenger receptors, such as SR-A1, SR-A2 and LOX-1. Lately, LOX-1, a type II membrane protein receptor of ox-LDL, has gained much importance in relation to effects of ox-LDL on endothelial biology. Endothelial cells primarily express LOX-1 as receptor for ox-LDL and ox-LDL has been shown to upregulate expression of LOX-1. In addition, ox-LDL promotes the growth a... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5273500 Tue, 27 Sep 2011 05:50:36 +0100 5273500 http://www.medworm.com/index.php?rid=5260423&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa70m473155154458%2F Content Type Journal ArticleCategory EditorialPages 1-2DOI 10.1007/s10557-011-6340-6Authors Raymond W. Sy, Concord Clinical School, University of Sydney, Sydney, AustraliaSaul B. Freedman, Concord Clinical School, University of Sydney, Sydney, Australia Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5260423 Tue, 20 Sep 2011 05:47:40 +0100 5260423 http://www.medworm.com/index.php?rid=5237003&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fdlp0506155243536%2F Content Type Journal ArticlePages 1-10DOI 10.1007/s10557-011-6334-4Authors Jonathan P. Piccini, Division of Cardiology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, USAThomas W. Wallace, Heart Clinic Arkansas, Little Rock, AR, USAManesh R. Patel, Division of Cardiology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, USARichard C. Becker, Division of Cardiology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5237003 Fri, 16 Sep 2011 16:43:25 +0100 5237003 http://www.medworm.com/index.php?rid=5237004&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk7q61k08m8306661%2F Content Type Journal ArticleCategory ISCP President’s PagePages 1-2DOI 10.1007/s10557-011-6338-0Authors Juan Carlos Kaski, Cardiovascular Sciences Research Centre, St. George’s, University of London, Cranmer Terrace, London, SW17 0RE UK Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5237004 Tue, 13 Sep 2011 15:52:39 +0100 5237004 http://www.medworm.com/index.php?rid=5237005&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj7wml31r72x65j19%2F Abstract  Hypertension is a common disease and a potent risk factor for cardiovascular disease. Tremendous strides have been made in understanding its genesis in the last 2 decades. Hypertension is often clustered with other cardiovascular risk factors, such as dyslipidemia and diabetes. The state of hypertension is often associated with increased vascular oxidative stress. Oxidative stress promotes proliferation and hypertrophy of vascular smooth muscle cell and collagen deposition, leading to thickening of the vascular media and narrowing of the vascular lumen. Oxidative stress also injures endothelium, impairs endothelium-dependent vascular relaxation and increases vascular contractile activity. Further, oxidative stress also oxidizes LDL-cholesterol. It has been shown t... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5237005 Mon, 12 Sep 2011 15:51:36 +0100 5237005 http://www.medworm.com/index.php?rid=5208331&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh863330381n0r92p%2F Abstract  Atherosclerosis is the first cause of death in industrialized countries. Together with traditional risk factors (male gender, hypercholesterolemia, hypertension, diabetes, smoking and age), non-traditional risk factors have also been described as predisposing to this disease. Among these, oxidized low density lipoproteins (OxLDL) have been described in correlation to many proatherogenic processes. Many of the effects of OxLDL are mediated by the lectin like oxidized low density lipoprotein receptor 1 (LOX-1), expressed on endothelial cells, macrophages, SMCs and platelets. LOX-1 is encoded by the lectin like oxidized low density lipoprotein receptor 1 (OLR1) gene, located in the p12.3–p13.2 region of human chromosome 12. Variations on this gene have been studied ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5208331 Fri, 09 Sep 2011 05:48:43 +0100 5208331 http://www.medworm.com/index.php?rid=5183642&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff8u616341605235u%2F Content Type Journal ArticlePages 1-11DOI 10.1007/s10557-011-6330-8Authors Magomed Khaidakov, Central Arkansas Veterans Healthcare Center and the University of Arkansas for Medical Sciences, 4301 W Markham, Slot 532, Little Rock, AR 72205, USAJawahar L. Mehta, Central Arkansas Veterans Healthcare Center and the University of Arkansas for Medical Sciences, 4301 W Markham, Slot 532, Little Rock, AR 72205, USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5183642 Wed, 31 Aug 2011 15:52:57 +0100 5183642 http://www.medworm.com/index.php?rid=5183641&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp8827110815w77kl%2F Abstract  Obesity is one of the most common lifestyle-related diseases. Being closely associated with insulin resistance, hypertension and dyslipidemia, it is also a component of metabolic syndrome and is involved in the development of atherosclerosis and cardiovascular and renal ailments. Obesity is also accompanied with a state of chronic inflammation. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), a receptor for oxidized low density lipoprotein (ox-LDL), is expressed not only in endothelial cells, but also in macrophages, vascular smooth muscle cells, platelets and adipocytes. LOX-1 binds multiple ligands, has diverse physiological functions and plays a critical role in the signal transduction. It may well turn out to be a key, or very important, factor... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5183641 Wed, 31 Aug 2011 15:52:57 +0100 5183641 http://www.medworm.com/index.php?rid=5183643&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx81v956544tu35n0%2F Conclusions  Dronedarone administered before and after MCAO reduces IS and improves FA and neurological outcome in transient cerebral ischemia. Content Type Journal ArticlePages 1-7DOI 10.1007/s10557-011-6336-2Authors Tobias Engelhorn, Department of Neuroradiology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, GermanyMarc A. Schwarz, Department of Neuroradiology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, GermanyGerd Heusch, Institute for Pathophysiology, University School of Medicine, Essen, GermanyArnd Doerfler, Department of Neuroradiology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, GermanyRainer Schulz, Institute for Physiology, Justus-Liebig University, Giessen, Germany Journal Cardiov... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5183643 Wed, 31 Aug 2011 15:52:55 +0100 5183643 http://www.medworm.com/index.php?rid=5161403&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp404650115m320q4%2F Abstract  The renin-angiotensin system (RAS) plays an important role in regulating blood pressure, water-salt balance and the pathogenesis of cardiovascular diseases. Angiotensin II (Ang II) is the physiologically active mediator and mediates the main pathophysiological actions in RAS. Ang II exerts the effects by activating its receptors, primarily type 1 (AT1R) and type 2 (AT2R). Most of the known pathophysiological effects of Ang II are mediated by AT1R activation. The precise physiological function of AT2R is still not clear. Generally, AT2R is considered to oppose the effects of AT1R. Lectin-like oxidized low-density lipoprotein scavenger receptor-1 (LOX-1) is one of the major receptors responsible for binding, internalizing and degrading ox-LDL. The activation of LOX-... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5161403 Mon, 22 Aug 2011 15:58:43 +0100 5161403 http://www.medworm.com/index.php?rid=5161404&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa7471nrw87774770%2F Abstract  Myocardial ischemia is the most common cause of mortality and morbidity in the developed countries and rapidly becoming a common malady in the developing countries. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), encoded by the OLR1 gene, is a scavenger receptor that plays a fundamental role in the genesis and progression of atherosclerosis and its complications. LOX-1 has been identified as a major receptor for oxidized low-density lipoprotein (ox-LDL) in endothelial cells, cardiomyocytes and fibroblast. In vitro and in vivo studies show that LOX-1 is upregulated during acute myocardial ischemia, and continues to be upregulated during chronic ischemia. Further, LOX-1 inhibition reduces ischemic myocardial injury and limits cardiac remodeling. LOX... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5161404 Wed, 17 Aug 2011 05:54:59 +0100 5161404 http://www.medworm.com/index.php?rid=5161405&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F31811047176m1732%2F Abstract  Since the discovery of oxidized low density lipoprotein (Ox-LDL), over 5,000 articles have appeared on the topic with over 400 articles appearing every year during the past decade. LDL contains esterified polyunsaturated fatty acid containing lipids, such as, phosphatidylcholine (PtdCho) and cholesterol esters (CE). Peroxidation of polyunsaturated fatty acid (PUFA) containing lipids has been known for a long time. Numerous studies have documented that peroxidized lipids as well as products derived from their decomposition, particularly aldehydes, have deleterious biological properties. This concept has been exemplified in the study of atherosclerosis. A plethora of in vitro and animal studies, as well as human epidemiological and correlatory studies, have supporte... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5161405 Tue, 16 Aug 2011 06:14:26 +0100 5161405 http://www.medworm.com/index.php?rid=5131913&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fjj3n79706n563014%2F Conclusions  The MAGIC study will yield important findings with regard to the prevalence and incidence of gastrointestinal complications and related risk factors for low-dose aspirin users. It may also report that use of anti-secretory agents such as proton pump inhibitors reduces the risk of such complications. Content Type Journal ArticlePages 1-10DOI 10.1007/s10557-011-6328-2Authors Hideki Origasa, Division of Biostatistics and Clinical Epidemiology, University of Toyama, 2630 Sugitani, Toyama, 930-0194 JapanShinya Goto, Department of Internal Medicine, Tokai University, Isehara, Tokyo, JapanKazuyuki Shimada, Department of Cardiology, Jichi Medical University, Shimotsuke, Tochigi, JapanShinichiro Uchiyama, Department of Neurology, Tokyo Women’s Medical Universit... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5131913 Sat, 13 Aug 2011 06:13:44 +0100 5131913 http://www.medworm.com/index.php?rid=5126180&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F02g235gk48858776%2F Conclusions  These results suggest that combining ivabradine with low dose bisoprolol in stable angina patients produces additional antianginal and anti-ischemic benefits and improves chronotropic reserve. Content Type Journal ArticlePages 1-7DOI 10.1007/s10557-011-6327-3Authors E. Amosova, National Medical University, Kiev, UkraineE. Andrejev, National Medical University, Kiev, UkraineI. Zaderey, National Medical University, Kiev, UkraineU. Rudenko, National Medical University, Kiev, UkraineC. Ceconi, Department of Cardiology, University of Ferrara, Corso Giovecca 203, 44121 Ferrara, ItalyR. Ferrari, Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Salvatore Maugeri Foundation, IRCCS, Lumezzane, Italy Journal Cardiovascular Drugs an... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5126180 Wed, 10 Aug 2011 15:40:02 +0100 5126180 http://www.medworm.com/index.php?rid=5126181&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F25144n72r47g4851%2F Abstract  There is much interest in the role of oxidant stress in an ever-increasing list of disease states. However, the precise mediator of oxidant stress and the stressor molecule/s have not been identified. Accordingly, trials of inhibitors of oxidant stress in animal models of disease states have met only limited success. The trials of traditional anti-oxidant vitamins have been largely unsuccessful in the treatment of a wide array of disease states in humans. Recent identification of LOX-1 in vascular endothelial cells and its activation by oxidant species have led to a marked improvement in our understanding of the pathology of several cardiovascular disease states. Here, we review the disease states where therapy targeted at LOX-1 inhibition might be helpful. C... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5126181 Mon, 08 Aug 2011 19:51:32 +0100 5126181 http://www.medworm.com/index.php?rid=5096755&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh24473654771857v%2F Abstract  LOX-1 is an endothelial receptor for oxidized low-density lipoprotein (oxLDL), a key molecule in the pathogenesis of atherosclerosis.The basal expression of LOX-1 is low but highly induced under the influence of proinflammatory and prooxidative stimuli in vascular endothelial cells, smooth muscle cells, macrophages, platelets and cardiomyocytes. Multiple lines of in vitro and in vivo studies have provided compelling evidence that LOX-1 promotes endothelial dysfunction and atherogenesis induced by oxLDL. The roles of LOX-1 in the development of atherosclerosis, however, are not simple as it had been considered. Evidence has been accumulating that LOX-1 recognizes not only oxLDL but other atherogenic lipoproteins, platelets, leukocytes and CRP. As results, LOX-1 not... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5096755 Mon, 01 Aug 2011 05:32:29 +0100 5096755 http://www.medworm.com/index.php?rid=5088083&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy4h112575712vll1%2F Abstract  The importance of the lectin-like oxidized LDL receptor (LOX-1) gene in cardiovascular and other diseases is slowly being revealed. LOX-1 gene expression appears to be a “canary in a coal mine” for atherogenesis, being strongly up-regulated early on in a number of cell types when they are activated, and predicting the sites of future disease. From this early time point the LOX-1 protein often participates in the disease process itself. While gene/protein expression can be regulated on a multiplicity of levels, the most basic and important mode of regulation is usually transcriptional. There are very few studies on the transcriptional regulation of the human LOX-1 promoter; fewer still on definitive mapping of the transcription factors involved. It is known tha... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5088083 Wed, 27 Jul 2011 15:51:26 +0100 5088083 http://www.medworm.com/index.php?rid=5088084&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F62u4856772077123%2F Abstract  The association between C-reactive protein (CRP) and cardiovascular disease has been under investigation for more than sixty years. Lately, findings from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial opened a new frontier: that of prescribing statins for vascular events risk reduction based upon the baseline CRP levels in otherwise healthy adults. Although the results from the JUPITER were impressive, ambiguities and arguments about this association have remained. Moreover, the results of a report by Heart Protection Study investigators have added to the complexities of the correlation between CRP levels and the risk of vascular events. In this review, a summary of the structural and functiona... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5088084 Tue, 26 Jul 2011 15:48:34 +0100 5088084 http://www.medworm.com/index.php?rid=5070127&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk80g1051j4173674%2F In conclusion, in isolated rat heart T1AM produces a cardioprotective effect which is mediated by a protein kinase C and KATP+-dependent pathway and is probably linked to modulation of mitochondrial permeability transition and/or ischemic arrest time. Content Type Journal ArticlePages 1-7DOI 10.1007/s10557-011-6320-xAuthors Sabina Frascarelli, Dipartimento di Scienze dell’Uomo e dell’Ambiente, University of Pisa, Via Roma 55, 56126 Pisa, ItalySandra Ghelardoni, Dipartimento di Scienze dell’Uomo e dell’Ambiente, University of Pisa, Via Roma 55, 56126 Pisa, ItalyGrazia Chiellini, Dipartimento di Scienze dell’Uomo e dell’Ambiente, University of Pisa, Via Roma 55, 56126 Pisa, ItalyElena Galli, Scuola Superiore S. Anna, Pisa, ItalyFrancesca Ronca, Dipartimento di Scienze dell... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5070127 Mon, 25 Jul 2011 05:33:54 +0100 5070127 http://www.medworm.com/index.php?rid=5070128&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3w7773v216112326%2F Conclusions  These results suggest that BK and the EETs share cardioprotective properties in a large animal model of RPCT. Content Type Journal ArticlePages 1-6DOI 10.1007/s10557-011-6321-9Authors Garrett J. Gross, Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USAJohn E. Baker, Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USAJeannine Moore, Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USAJohn R. Falck, Departments of Biochemistry and Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USAKasem Nithipatikom, Department o... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5070128 Mon, 25 Jul 2011 05:33:53 +0100 5070128 http://www.medworm.com/index.php?rid=5063517&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fpr6w132505w08405%2F Conclusions  Aliskiren causes neurohumoral suppression in heart failure, even in patients treated with ≥recommended-dose of ACE inhibitor. Content Type Journal ArticlePages 1-7DOI 10.1007/s10557-011-6319-3Authors Novalia P. Sidik, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA UKScott D. Solomon, Cardiovascular Division, Brigham & Women’s Hospital, Boston, MA, USARoberto Latini, Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, ItalyAldo P. Maggioni, ANMCO Research Center, Florence, ItalyMelanie Wright, Novartis Pharma AG, Basel, SwitzerlandClaudio R. Gimpelewicz, Novartis Pharma AG, Basel, SwitzerlandBertram Pitt, University of Michigan, Ann Arbor, MI... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5063517 Thu, 21 Jul 2011 18:04:43 +0100 5063517 http://www.medworm.com/index.php?rid=5063518&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0274k41614730318%2F Content Type Journal ArticlePages 1-3DOI 10.1007/s10557-011-6316-6Authors Lionel H. Opie, Hatter Cardiovascular Research Institute, Department of Medicine, University of Cape Town Faculty of Health Sciences and Groote Schuur Hospital, Observatory, Cape Town, 7925 South Africa Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5063518 Tue, 19 Jul 2011 23:37:41 +0100 5063518 http://www.medworm.com/index.php?rid=5063519&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh314j08t4m243711%2F Content Type Journal ArticlePages 1-2DOI 10.1007/s10557-011-6317-5Authors Juan-Carlos Kaski, St. George’s, University of London, London, UK Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5063519 Tue, 19 Jul 2011 05:44:37 +0100 5063519 http://www.medworm.com/index.php?rid=5063520&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1005837kp8535443%2F Content Type Journal ArticlePages 1-3DOI 10.1007/s10557-011-6318-4Authors Alexander H. Maass, Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5063520 Tue, 19 Jul 2011 05:44:35 +0100 5063520 http://www.medworm.com/index.php?rid=5030270&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu2qg3l51v5523671%2F Conclusions  This meta-analysis suggests that CRT could improve the prognosis in patients with mild heart failure and ventricular dyssynchrony, but these improvements are accompanied by more adverse events. Since most patients in the included trials had received ICD therapy, our analysis suggests that CRT could offer an additional benefit. Content Type Journal ArticlePages 1-10DOI 10.1007/s10557-011-6313-9Authors Ronghui Tu, Department of Geriatric Cardiology, First Afiliated Hospital, Guangxi Medical University, 22 Shuangyong Road, 530000 Nanning, Guangxi, People’s Republic of ChinaGuoqiang Zhong, Department of Geriatric Cardiology, First Afiliated Hospital, Guangxi Medical University, 22 Shuangyong Road, 530000 Nanning, Guangxi, People’s Republic of ChinaZhiyu ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5030270 Wed, 13 Jul 2011 06:03:16 +0100 5030270 http://www.medworm.com/index.php?rid=5030271&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0v48l328p76v617x%2F Conclusion  The effect of pre-hospital initiation of high bolus dose tirofiban on myocardial reperfusion, as determined by ST-segment resolution is highest in the elderly patients. However, this was associated with a trend towards more bleeding complications, resulting in a balanced clinical effect after 30-day follow-up. Future studies should evaluate whether the elderly STEMI patient may benefit from highly effective and safer antiplatelet therapy. Content Type Journal ArticlePages 1-8DOI 10.1007/s10557-011-6314-8Authors Renicus S. Hermanides, Department of Cardiology, Isala Klinieken. locatie Weezenlanden, Groot Wezenland 20, 8011 JW Zwolle, The NetherlandsGert van Houwelingen, Department of Cardiology, Medisch Spectrum Twente, Enschede, The NetherlandsJan Paul O... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5030271 Mon, 11 Jul 2011 05:35:15 +0100 5030271 http://www.medworm.com/index.php?rid=5009801&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg1654158868258j5%2F Content Type Journal ArticlePages 1-2DOI 10.1007/s10557-011-6315-7Authors Katsuyuki Ando, Department of Nephrology and Endocrinology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113–8655 JapanMasakazu Haneda, Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, 1-1, 2–1 Midorigaokahigashi, Asahikawa, Hokkaido 078–8510, JapanSadayoshi Ito, Division of Nephrology, Endocrinology, and Vascular Medicine, Department of Internal Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980–8574 JapanNaoki Kashihara, Division of Nephrology, Department of Internal Medicine, Kawasaki Medical School, 557 Matsushima, Kurashiki, Okayama 701–0192, JapanKoichi Node, Department of ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=5009801 Wed, 06 Jul 2011 05:53:54 +0100 5009801 http://www.medworm.com/index.php?rid=4946486&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe37n45u83p301136%2F Conclusion  Atorvastatin conferred significant protection against MI-RP injury and alleviated HFr induced IRS possibly by increasing NOS expression through Akt dependent pathway. Content Type Journal ArticlePages 1-13DOI 10.1007/s10557-011-6312-xAuthors Prem Prakash, Pharmacology Division, CSIR-Central Drug Research Institute, 1. M.G. Marg, Lucknow, UP 226001, IndiaVivek Khanna, Pharmacology Division, CSIR-Central Drug Research Institute, 1. M.G. Marg, Lucknow, UP 226001, IndiaVishal Singh, Pharmacology Division, CSIR-Central Drug Research Institute, 1. M.G. Marg, Lucknow, UP 226001, IndiaAnupam Jyoti, Pharmacology Division, CSIR-Central Drug Research Institute, 1. M.G. Marg, Lucknow, UP 226001, IndiaManish Jain, Pharmacology Division, CSIR-Central Drug Research Insti... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4946486 Tue, 14 Jun 2011 05:50:37 +0100 4946486 http://www.medworm.com/index.php?rid=4913452&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft75014n265n306k6%2F Conclusion  Inhibition of PDEs prevents the mPTP opening by inactivating GSK-3β through PKA and PKG. GSK-3β is a common downstream target of PKA and PKG. Inhibition of PDEs may be a useful approach to prevent reperfusion injury. Content Type Journal ArticlePages 1-8DOI 10.1007/s10557-011-6310-zAuthors Guillaume Chanoit, Department of Anesthesiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USAJuan Zhou, Department of Anesthesiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USASungRyul Lee, Department of Anesthesiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USARachel McIntosh, Department of Anesthesiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4913452 Sat, 04 Jun 2011 06:01:55 +0100 4913452 http://www.medworm.com/index.php?rid=4903986&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg312p007w6874204%2F Abstract  Despite recent studies suggesting that the heart has instrinsic mechanisms of self-regeneration following myocardial infarction, it cannot regenerate itself to an optimal level. Mesenchymal stem cells (MSCs) are currently being investigated for regeneration of mesenchyme-derived tissues, such as bone, cartilage and tendon. In vitro evidence suggests that MSCs can also differentiate into cardiomyogenic and vasculogenic lineages, offering another cell source for cardiovascular regeneration. In vivo, MSCs may contribute to the re-growth and protection of vasculature and cardiomyocytes, mediated by paracrine actions, and/or persist within the myocardium in a differentiated state; although proof of cardiomyocytic phenotype and functional integration remains elusive. He... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4903986 Fri, 03 Jun 2011 05:57:22 +0100 4903986 http://www.medworm.com/index.php?rid=4903987&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp52x477271828n21%2F Conclusions  The present trial is expected to clarify whether the sympatholytic CCB azelnidipine is a beneficial second-line choice for RAS inhibitor-treated hypertensive patients with CKD, such as diabetic nephropathy. Content Type Journal ArticlePages 1-7DOI 10.1007/s10557-011-6309-5Authors Katsuyuki Ando, Department of Nephrology and Endocrinology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655 JapanMasakazu Haneda, Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, 1-1, 2-1 Midorigaokahigashi, Asahikawa, Hokkaido 078-8510, JapanSadayoshi Ito, Division of Nephrology, Endocrinology, and Vascular Medicine, Department of Internal Medicine, Tohoku University Graduate School of Medicin... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4903987 Fri, 03 Jun 2011 05:57:21 +0100 4903987 http://www.medworm.com/index.php?rid=4903988&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff24qv173016l6g45%2F Content Type Journal ArticlePages 1-5DOI 10.1007/s10557-011-6308-6Authors Ruy Andrade N. Louzada, Departamento de Biociências e Atividade Física, CCS, Escola de Educação Física e Desportos, Ilha do Fundão, Universidade Federal do Rio de Janeiro (UFRJ), Carlos Chagas Filho av, 540, 21941–599 Rio de Janeiro, RJ, BrazilJoão Pedro Saar Werneck-de-Castro, Departamento de Biociências e Atividade Física, CCS, Escola de Educação Física e Desportos, Ilha do Fundão, Universidade Federal do Rio de Janeiro (UFRJ), Carlos Chagas Filho av, 540, 21941–599 Rio de Janeiro, RJ, Brazil Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4903988 Wed, 01 Jun 2011 05:58:37 +0100 4903988 http://www.medworm.com/index.php?rid=4903990&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl436726117177412%2F Conclusion  We found that polymorphisms of the β1-AR and β2-AR genes are associated with differential LV remodeling in patients treated with a β1 receptor antagonist following STEMI. Content Type Journal ArticlePages 1-8DOI 10.1007/s10557-011-6307-7Authors Rhondalyn C. McLean, Division of Cardiology, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD, USAGlenn A. Hirsch, Division of Cardiology, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD, USALewis C. Becker, Division of Cardiology, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD, USALaura Kasch-Semenza, The Johns Hopkins School of Medicine, The McKusick-Nathans Institute of Genetic Medicine, Baltimore, MD, USAGary Gerstenblit... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4903990 Mon, 30 May 2011 16:49:44 +0100 4903990 http://www.medworm.com/index.php?rid=4903989&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl71j3l87218qg763%2F Conclusions  In the era of guidelines-adjusted treatment for CVD secondary prevention, omega-3 fatty acids do not appear to reduce SCD. Content Type Journal ArticlePages 1-7DOI 10.1007/s10557-011-6306-8Authors Qi Chen, Institute of Geriatric Cardiology, The General Hospital of the People’s Liberation Army, 28 Fuxing Road, Beijing, CountryLiu-Quan Cheng, Department of Radiology, The General Hospital of the People’s Liberation Army, 28 Fuxing Road, Beijing, CountryTie-Hui Xiao, Institute of Geriatric Cardiology, The General Hospital of the People’s Liberation Army, 28 Fuxing Road, Beijing, CountryYu-Xiao Zhang, Institute of Geriatric Cardiology, The General Hospital of the People’s Liberation Army, 28 Fuxing Road, Beijing, CountryMei Zhu, Institute of Geriatric Car... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4903989 Mon, 30 May 2011 16:49:44 +0100 4903989 http://www.medworm.com/index.php?rid=4903991&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc77501u4j3h64223%2F Conclusions  Our results indicate that β-elemene is effective in protecting the endothelial cells from injury induced by hydrogen peroxide in vitro, inhibiting smooth muscle cell proliferation/migration and inhibiting neointima formation in vivo after vascular injury. Content Type Journal ArticlePages 1-10DOI 10.1007/s10557-011-6305-9Authors Lingyan Wu, Key Laboratory of Biorheological Science and Technology (Chongqing University), Ministry of Education, Chongqing Engineering Lab. in Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400044 ChinaGuixue Wang, Key Laboratory of Biorheological Science and Technology (Chongqing University), Ministry of Education, Chongqing Engineering Lab. in Vascular Implants, Bioengineering College of Chongq... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4903991 Mon, 23 May 2011 17:04:02 +0100 4903991 http://www.medworm.com/index.php?rid=4842755&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F043v352m672840j4%2F Conclusion  Intravenous enoxaparin induced target F Xa inhibition (>0.6 IU/ml) for 60 min in 82% of study patients. During the 6 h of monitoring, a decrease of thrombin generation (F1 + 2) and sP-selectin levels were observed. Content Type Journal ArticlePages 1-8DOI 10.1007/s10557-011-6301-0Authors J. Kvasnička, Center for Thrombosis Research, General Teaching Hospital, Charles University, Karlovo n. 32, Prague, 121 11 Czech RepublicJ. Horák, 2nd Department of Internal Medicine, General Teaching Hospital, Charles University, U nemocnice 2, Prague, Czech RepublicZ. Zenáhlíková, Center for Thrombosis Research, General Teaching Hospital, Charles University, Karlovo n. 32, Prague, 121 11 Czech RepublicTomáš Kvasnička, Center for Thrombosis R... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4842755 Mon, 16 May 2011 08:42:09 +0100 4842755 http://www.medworm.com/index.php?rid=4821802&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc7338g2673556wq0%2F Conclusions  Late-ischemia/early reperfusion therapy with esmolol + milrinone additively reduces LV-IS associated with robust activation of myocardial PKA and subsequent Akt-antiapoptotic pathway. Content Type Journal ArticlePages 1-10DOI 10.1007/s10557-011-6302-zAuthors Ming-He Huang, Department of Internal Medicine, Cardiology Division (M-HH, YW, VN, SR, BFU, KF), University of Texas Medical Branch, Galveston, TX, USAYewen Wu, Department of Internal Medicine, Cardiology Division (M-HH, YW, VN, SR, BFU, KF), University of Texas Medical Branch, Galveston, TX, USAVincent Nguyen, Department of Internal Medicine, Cardiology Division (M-HH, YW, VN, SR, BFU, KF), University of Texas Medical Branch, Galveston, TX, USASaurabh Rastogi, Department of Internal Medicine, Car... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4821802 Wed, 11 May 2011 15:46:40 +0100 4821802 http://www.medworm.com/index.php?rid=4805752&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx781gx8v25631832%2F Conclusion  The beneficial effect of dronedarone is attributed to cardioprotective properties, possibly through attenuation of calcium overload during myocardial ischemia/reperfusion. Content Type Journal ArticlePages 1-5DOI 10.1007/s10557-011-6300-1Authors Andreas Skyschally, Institut für Pathophysiologie, Universitätsklinikum Essen, Hufelandstr. 55, 45122 Essen, GermanyGerd Heusch, Institut für Pathophysiologie, Universitätsklinikum Essen, Hufelandstr. 55, 45122 Essen, Germany Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4805752 Wed, 04 May 2011 14:51:29 +0100 4805752 http://www.medworm.com/index.php?rid=4782299&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy75167754706x42n%2F Content Type Journal ArticlePages 1-4DOI 10.1007/s10557-011-6298-4Authors Masatsugu Hori, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka, 537-8511 Japan Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4782299 Mon, 02 May 2011 14:59:29 +0100 4782299 http://www.medworm.com/index.php?rid=4745113&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6vu885m8t59r1135%2F Abstract  Heart failure is one of the common end stages of cardiovascular diseases, the leading cause of death in developed countries. Molecular mechanisms underlying the development of heart failure remain elusive but there is a consistent observation of chronic immune activation and aberrant microRNA (miRNA) expression that is present in failing hearts. This review will focus on the interplay between the immune system and miRNAs as factors that play a role during the development of heart failure. Several studies have shown that heart failure patients can be characterized by a sustained innate immune activation. The role of inflammatory signaling is discussed and TLR4 signaling, IL-1β, TNFα and IL-6 expression appears to coincide with the development of heart failure. Fu... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4745113 Tue, 19 Apr 2011 07:13:14 +0100 4745113 http://www.medworm.com/index.php?rid=4745115&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd488177586221v8v%2F Conclusions  Both early and delayed administrations of G-CSF can improve electrophysiological properties after myocardial ischemia, but have no beneficial effects on LV mechanical remodeling. Content Type Journal ArticlePages 1-12DOI 10.1007/s10557-011-6294-8Authors Hong-Mei Liu, Institute of Cardiovascular Diseases, Pingjin Hospital, Medical College of Chinese People’s Armed Police Forces, 220 Cheng-Lin Road, Tianjin, 300162 ChinaTao Luo, Institute of Cardiovascular Diseases, Pingjin Hospital, Medical College of Chinese People’s Armed Police Forces, 220 Cheng-Lin Road, Tianjin, 300162 ChinaXin Zhou, Institute of Cardiovascular Diseases, Pingjin Hospital, Medical College of Chinese People’s Armed Police Forces, 220 Cheng-Lin Road, Tianjin, 300162 ChinaLin Cai, I... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4745115 Tue, 19 Apr 2011 07:13:12 +0100 4745115 http://www.medworm.com/index.php?rid=4745114&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm15606158852tr09%2F Content Type Journal ArticlePages 1-2DOI 10.1007/s10557-011-6297-5Authors Juan-Carlos Kaski, Cardiovascular Sciences Research Centre, St. George’s, University of London, London, UK Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4745114 Tue, 19 Apr 2011 07:13:12 +0100 4745114 http://www.medworm.com/index.php?rid=4725493&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fmh863114v771204j%2F Content Type Journal ArticlePages 1-2DOI 10.1007/s10557-011-6296-6Authors Willem J. Remme, Sticares Cardiovascular Research Institute, Oever 1-5, 3161GR, Rhoon, The Netherlands Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4725493 Thu, 14 Apr 2011 16:59:40 +0100 4725493 http://www.medworm.com/index.php?rid=4710141&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj716250rt4328433%2F Content Type Journal ArticlePages 1-3DOI 10.1007/s10557-011-6295-7Authors Dimitrios Farmakis, Athens University Medical School, Second Department of Cardiology, Attikon University Hospital, 28 Doukissis Plakentias St, 11523 Athens, GreeceGerasimos Filippatos, Athens University Medical School, Second Department of Cardiology, Attikon University Hospital, 28 Doukissis Plakentias St, 11523 Athens, Greece Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4710141 Mon, 11 Apr 2011 15:50:17 +0100 4710141 http://www.medworm.com/index.php?rid=4710142&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe618h745u24t7p75%2F Conclusion  The strategy of prolonging the bivalirudin infusion at a reduced infusion rate for 4 h after completion of the PCI procedure was explored and offers promising results. Content Type Journal ArticlePages 1-10DOI 10.1007/s10557-011-6293-9Authors Lynette R. Moser, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Suite 2190, Detroit, MI 48201, USACarrie W. Nemerovski, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Suite 2190, Detroit, MI 48201, USAKelley L. Good, Baxter Healthcare, McGraw Park, IL, USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4710142 Fri, 08 Apr 2011 17:00:24 +0100 4710142 http://www.medworm.com/index.php?rid=4686150&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk5806851905m6347%2F Abstract  Research into small non-coding RNAs (ncRNA) has fundamentally transformed our understanding of gene regulatory networks, especially at the post-transcriptional level. Although much is now known about the basic biology of small ncRNAs, our ability to recognize the impact of small ncRNA in disease states is preliminary, and the ability to effectively target them in vivo is very limited. However, given the larger and growing focus on targeting RNAs for disease therapeutics, what we do know about the intrinsic biology of these small RNAs makes them potentially attractive targets for pharmacologic manipulation. With that in mind, this review provides an introduction to the biology of small ncRNA, using microRNA (miRNA) and small nucleolar RNA (snoRNA) as examples. ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4686150 Tue, 05 Apr 2011 16:56:43 +0100 4686150 http://www.medworm.com/index.php?rid=4686151&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj2m3p62j6765h802%2F Abstract    Content Type Journal ArticlePages 1-1DOI 10.1007/s10557-011-6292-xAuthors Douglas L. Mann, Washington University School of Medicine, St. Louis, MO, USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4686151 Tue, 05 Apr 2011 16:56:41 +0100 4686151 http://www.medworm.com/index.php?rid=4664865&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F77u10513p50235q0%2F Content Type Journal ArticlePages 1-2DOI 10.1007/s10557-011-6286-8 Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4664865 Tue, 29 Mar 2011 06:04:58 +0100 4664865 http://www.medworm.com/index.php?rid=4644105&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7624307982895085%2F This article reviews current evidence regarding management of AMI in the elderly. Content Type Journal ArticlePages 1-10DOI 10.1007/s10557-011-6288-6Authors Amelia Carro, Cardiovascular Sciences Research Centre, Division of Clinical Sciences, St George’s University of London, Cranmer Terrace, London, SW17 0RE UKRachel Bastiaenen, Cardiovascular Sciences Research Centre, Division of Clinical Sciences, St George’s University of London, Cranmer Terrace, London, SW17 0RE UKJuan Carlos Kaski, Cardiovascular Sciences Research Centre, Division of Clinical Sciences, St George’s University of London, Cranmer Terrace, London, SW17 0RE UK Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4644105 Fri, 25 Mar 2011 05:48:33 +0100 4644105 http://www.medworm.com/index.php?rid=4637006&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F089435t3m3250845%2F Abstract  MicroRNAs (miRNAs) are endogenous, short (~22 nucleotide), evolutionarily conserved, non-coding RNAs that regulate gene expression at the post-transcriptional level. Recent evidence suggests that miRNAs are differentially expressed in the failing myocardium and play an important role in progression of heart failure by targeting genes that govern diverse functions in cardiac remodeling process including myocyte hypertrophy, excitation-contraction coupling, increased myocyte loss, and myocardial fibrosis. In addition to their role in adverse cardiac remodeling, miRNAs hold promise as biomarkers of disease progression in heart failure given their presence in circulation and enhanced stability. Further development of miR-based therapeutics may allow for modulation of ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4637006 Tue, 22 Mar 2011 18:09:24 +0100 4637006 http://www.medworm.com/index.php?rid=4632272&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl3175k147t17753n%2F Conclusions  VDR hormone calcitriol and its analog paricalcitol exhibit more potent effects than the prehormone calcidiol in cardiomyocytes. Content Type Journal ArticlePages 1-8DOI 10.1007/s10557-011-6287-7Authors J. Ruth Wu-Wong, University of Illinois at Chicago, 2201 W. Campbell Park Dr., Suite 13, Chicago, IL 60612, USAYung-Wu Chen, VidaGene, Chicago, IL USAMasaki Nakane, VidaGene, Chicago, IL USAMyles Wolf, University of Miami Miller School of Medicine, Miami, FL USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4632272 Mon, 21 Mar 2011 19:11:10 +0100 4632272 http://www.medworm.com/index.php?rid=4616501&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6132241928581617%2F Conclusions  The addition of fenofibric acid to moderate-dose statin in patients whose LDL-C was optimal but whose triglycerides remained >200 mg/dL led to additional improvements in non–HDL-C, ApoB, HDL-C, and triglycerides that resulted in greater proportions of patients attaining optimal levels of the individual parameters as well as simultaneously achieving optimal levels of these parameters and LDL-C. Content Type Journal ArticlePages 1-9DOI 10.1007/s10557-011-6280-1Authors Christie M. Ballantyne, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, 6565 Fannin St., Room A601, Houston, TX 77030, USAPeter H. Jones, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, 6565 Fannin St., Room A601, Houston, TX ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4616501 Thu, 17 Mar 2011 18:32:43 +0100 4616501 http://www.medworm.com/index.php?rid=4541356&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6620w4251r871316%2F Content Type Journal ArticlePages 1-1DOI 10.1007/s10557-011-6282-zAuthors Lionel H. Opie, University of Cape Town Medical School, Cape Town, South Africa Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4541356 Wed, 23 Feb 2011 23:14:39 +0100 4541356 http://www.medworm.com/index.php?rid=4513357&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F88838m62013l3070%2F Abstract  The clinical trials described in this article were presented at the Late Breaking Trials and the Clinical Science: Clinical Reports sessions of the American Heart Association Congress held in November 2010 in Chicago. The sessions and topics chosen for this article reflect the scope of interest of Cardiovascular Drugs and Therapy. The presentations should be considered preliminary, as further analyses may be done, which could alter the final publication of the results of these studies. PROTECT (ProBNP Outpatient Tailored Chronic Heart Failure Therapy) was designed to test the hypothesis that adjustment of intensity of chronic heart failure (HF) therapy on the basis of NT-proBNP plasma level monitoring would improve outcomes. The results provided some support of th... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4513357 Mon, 21 Feb 2011 17:08:19 +0100 4513357 http://www.medworm.com/index.php?rid=4495955&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl645l6431462m908%2F Content Type Journal ArticlePages 1-3DOI 10.1007/s10557-011-6281-0Authors Saloni Gill, BABS, School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Biological Sciences Building, D26, Sydney, NSW 2052, AustraliaAndrew J. Brown, BABS, School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Biological Sciences Building, D26, Sydney, NSW 2052, Australia Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4495955 Wed, 16 Feb 2011 07:02:30 +0100 4495955 http://www.medworm.com/index.php?rid=4442703&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn52181k28n431317%2F Conclusions  Chronic istaroxime improves cardiac function and heart rate variability in Bio TO.2 Syrian hamster model of progressive heart failure. Content Type Journal ArticlePages 1-6DOI 10.1007/s10557-011-6283-yAuthors Pietro Lo Giudice, Research and Development, Pharmacology Department, Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina km 30.400, 00040 Pomezia, Rome ItalyGiovan Giuseppe Mattera, Research and Development, Pharmacology Department, Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina km 30.400, 00040 Pomezia, Rome ItalyJean-Pierre Gagnol, University of Montpellier 1 and CNRS UMR5232, Montpellier, FranceFranco Borsini, Research and Development, Pharmacology Department, Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4442703 Thu, 03 Feb 2011 21:03:57 +0100 4442703 http://www.medworm.com/index.php?rid=4442704&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd730172819132557%2F Conclusions  The FSQ performed well in this study, provided additional information to the MLwHF questionnaire and allowed interesting comparisons with other chronic medical conditions. The FSQ may be a useful general QoL instrument for studies in CHF. Content Type Journal ArticlePages 1-9DOI 10.1007/s10557-011-6284-xAuthors Siobhan Gallanagh, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland UKDavide Castagno, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland UKBen Wilson, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland UKErland Erdmann, Department III of Internal Medicine, University of Cologne, Cologne, GermanyFaiez Zannad, University of Nancy, Nancy, FranceWil... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4442704 Thu, 03 Feb 2011 21:03:53 +0100 4442704 http://www.medworm.com/index.php?rid=4400800&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2512nu7t2721512q%2F Conclusion  AMPK activation inhibits eNOS down-regulation and Nox4-derived ROS accumulation induced by Hcy in EPCs, and may contribute to the protective effects of atorvastatin on endothelial function. Content Type Journal ArticlePages 1-9DOI 10.1007/s10557-010-6277-1Authors Fang Jia, Department of Cardiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road II, Shanghai, 200025 People’s Republic of ChinaChunfang Wu, Department of Cardiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road II, Shanghai, 200025 People’s Republic of ChinaZhenyue Chen, Department of Cardiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road II, Shanghai, 200025 People’s Republic of... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4400800 Fri, 21 Jan 2011 20:24:23 +0100 4400800 http://www.medworm.com/index.php?rid=4344154&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj685538x54480w34%2F Conclusion  Protection afforded by β-ARs stimulation, depends on activation of both β1-AR and β2-ARs but not β3-AR. With functional recovery as endpoint, results suggest involvement of NO in β1/β2-AR preconditioning and the Gi protein in β2-AR preconditioning. Both PKA and PI3-K activation were essential for β1/β2-AR cardioprotection. Content Type Journal ArticlePages 1-16DOI 10.1007/s10557-010-6275-3Authors Ruduwaan Salie, Division Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, 7505 Republic of South AfricaJohannes A. Moolman, Division Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, 7505 Republic of South Afric... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4344154 Tue, 11 Jan 2011 18:03:06 +0100 4344154 http://www.medworm.com/index.php?rid=4325082&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv132685u8g848190%2F Abstract  Inhibition of the renin-angiotensin system has been a highly successful therapeutic approach for the prevention of hypertension-related end organ damage. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers lower blood pressure and reduce morbidity and mortality in patients with cardiovascular and kidney disease. However, progression to end-stage disease remains common in these patient populations. A compensatory increase in plasma renin activity occurs with the use of either angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, thus causing increased levels of angiotensin II, which may limit the therapeutic effectiveness of these agents. The direct renin inhibitor, aliskiren, suppresses the renin-angiotensin system... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4325082 Thu, 06 Jan 2011 17:55:05 +0100 4325082 http://www.medworm.com/index.php?rid=4322938&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F578w042l874g1332%2F Content Type Journal ArticlePages 1-2DOI 10.1007/s10557-010-6279-zAuthors Amirhossein Sahebkar, Cardiovascular Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences (MUMS), P. O. Box: 91775-1365, Mashhad, Iran Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4322938 Wed, 05 Jan 2011 16:50:42 +0100 4322938 http://www.medworm.com/index.php?rid=4319236&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk0u45005k2010722%2F Content Type Journal ArticleDOI 10.1007/s10557-010-6276-2Authors Juan-Carlos Kaski, St. George’s, University of London, London, UK Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4319236 Tue, 04 Jan 2011 17:53:22 +0100 4319236 http://www.medworm.com/index.php?rid=4285718&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F83qq351873703j30%2F Conclusions  A significantly greater proportion of T2DM patients achieved individual and combined lipid targets when treated with the combination of R + FA than corresponding-dose R monotherapies. Content Type Journal ArticleDOI 10.1007/s10557-010-6273-5Authors Robert S. Rosenson, Mount Sinai Heart, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6574, USADawn M. Carlson, Abbott, Abbott Park, IL USAMaureen T. Kelly, Abbott, Abbott Park, IL USACarolyn M. Setze, Abbott, Abbott Park, IL USABoaz Hirshberg, AstraZeneca LP, Wilmington, DE USAJames C. Stolzenbach, Abbott, Abbott Park, IL USALaura A. Williams, Abbott, Abbott Park, IL USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascul... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4285718 Mon, 20 Dec 2010 22:17:23 +0100 4285718 http://www.medworm.com/index.php?rid=4267299&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb3321t416267587p%2F Conclusions  Our study suggests that RAS blockers achieve their beneficial effects by their enhancement of adipocyte secretion of apelin. Content Type Journal ArticleDOI 10.1007/s10557-010-6274-4Authors Wei-Wen Hung, Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanTusty-Jiuan Hsieh, Department of Medical Genetics, College of Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanTzu Lin, Department of Medical Genetics, College of Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanPong-Chun Chou, Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanPi-Jung Hsiao, Division of Endocrinology and Metabolism, D... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4267299 Wed, 15 Dec 2010 15:55:36 +0100 4267299 http://www.medworm.com/index.php?rid=4242516&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl03723886p401575%2F Abstract  HMG Co-A reductase inhibitors (statins) are a group of drugs which lower cholesterol by inhibiting the conversion of HMG Co-A to mevalonate early in the cholesterol synthetic pathway. They are used in the primary and secondary prevention of cardiovascular events in patients deemed to be at increased risk and their benefit in patients with ischaemic heart disease is well supported. Their use in patients with heart failure (HF) however, is controversial. Evidence from observational and mechanistic studies suggests that statins should benefit patients with HF. However, larger randomised controlled trials have failed to demonstrate these expected benefits. The aim of this review article is to summarise the data from trials of statin use in patients with HF and attempt... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4242516 Mon, 06 Dec 2010 18:46:51 +0100 4242516 http://www.medworm.com/index.php?rid=4191544&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa59167mt68375uw3%2F Content Type Journal ArticleDOI 10.1007/s10557-010-6272-6Authors Jay N. Cohn, University of Minnesota, Minneapolis, MN USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4191544 Fri, 19 Nov 2010 17:03:03 +0100 4191544 http://www.medworm.com/index.php?rid=4187368&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fnwv252r05257118w%2F Abstract  Cardiovascular risk is closely associated with insulin resistance and type 2 diabetes. Therapy based on the actions of GLP-1 is currently seen as a novel approach to treat this disease. The aims of this study was therefore to use an animal model to determine whether (i) pre-treatment of obese, insulin resistant but pre-diabetic rats with a DPP4 inhibitor, PFK275-055, could protect the heart from ischaemia/reperfusion injury and (ii) the possible mechanisms involved in such protection. Obese, pre-diabetic rats (DIO) were treated for 4 weeks with 10 mg/kg/day of the DPP4 inhibitor PFK275-055. Ex vivo perfusion was used to subject hearts to ischaemia/reperfusion to determine infarct size, functional recovery and post-ischaemic activation of proteins associat... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4187368 Thu, 18 Nov 2010 17:54:43 +0100 4187368 http://www.medworm.com/index.php?rid=4089512&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd223v020742682u0%2F Conclusion  EPO affords more potent protection against infarction than does CEPO by distinct activation of signaling leading to phosphorylation of pro-survival protein kinases in mitochondria upon reperfusion. Content Type Journal ArticleDOI 10.1007/s10557-010-6265-5Authors Takahiro Sato, Division of Cardiology, Second Department of Internal Medicine, Sapporo Medical University School of Medicine, South-1 West-16, Chuo-ku, Sapporo, 060-8543 JapanMasaya Tanno, Division of Cardiology, Second Department of Internal Medicine, Sapporo Medical University School of Medicine, South-1 West-16, Chuo-ku, Sapporo, 060-8543 JapanTakayuki Miki, Division of Cardiology, Second Department of Internal Medicine, Sapporo Medical University School of Medicine, South-1 West-16, Chuo-ku, Sa... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4089512 Sat, 16 Oct 2010 09:03:25 +0100 4089512 http://www.medworm.com/index.php?rid=4089513&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv76197513880687l%2F Conclusion  In conclusion, rosuvastatin 5 mg + fenofibric acid 135 mg resulted in comprehensive improvements in the lipid profile of patients with mixed dyslipidemia without unanticipated adverse events. Content Type Journal ArticleDOI 10.1007/s10557-010-6266-4Authors Eli M. Roth, Sterling Research Group, 2230 Auburn Avenue, Cincinnati, OH 45219, USARobert S. Rosenson, Mount Sinai School of Medicine, New York, NY USADawn M. Carlson, Abbott, Abbott Park, IL USASandra M. Fukumoto, Abbott, Abbott Park, IL USACarolyn M. Setze, Abbott, Abbott Park, IL USAJames W. Blasetto, AstraZeneca LP, Wilmington, DE USANardev S. Khurmi, AstraZeneca LP, Wilmington, DE USAJames C. Stolzenbach, Abbott, Abbott Park, IL USALaura A. Williams, Abbott, Abbott Park, IL USA Jour... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4089513 Sat, 16 Oct 2010 09:03:24 +0100 4089513 http://www.medworm.com/index.php?rid=4068269&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Frn54643329177rn7%2F Content Type Journal ArticleDOI 10.1007/s10557-010-6267-3Authors Zoltan Ungvari, Reynolds Oklahoma Center on Aging, Donald W. Reynolds Department of Geriatric Medicine, University of Oklahoma Health Sciences Center, 975 N. E. 10th Street - BRC 1303, Oklahoma City, OK 73104, USAAnna Csiszar, Reynolds Oklahoma Center on Aging, Donald W. Reynolds Department of Geriatric Medicine, University of Oklahoma Health Sciences Center, 975 N. E. 10th Street - BRC 1303, Oklahoma City, OK 73104, USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4068269 Mon, 11 Oct 2010 16:48:44 +0100 4068269 http://www.medworm.com/index.php?rid=4037524&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F33532112jqm4p334%2F Conclusions  Late postprandial triglyceride responders have attenuated clearance of large VLDL particles, but they were more responsive to fenofibrate. Content Type Journal ArticleDOI 10.1007/s10557-010-6264-6Authors Robert S. Rosenson, Mount Sinai Heart, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1070, New York, NY 10017, USAIrene B. Helenowski, Department of Preventive Medicine, Northwestern University, Chicago, IL USAChristine C. Tangney, Department of Clinical Nutrition, Rush University Medical Center, Chicago, IL USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4037524 Mon, 04 Oct 2010 14:48:03 +0100 4037524 http://www.medworm.com/index.php?rid=4026156&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc82wq1719v51g703%2F Content Type Journal ArticleDOI 10.1007/s10557-010-6268-2Authors Carrie M. Quinn, Division of Cardiovascular Diseases and Cardiovascular Research Institute, University of Kansas Medical Center and Hospital, 3901 Rainbow Blvd, Rm. 1001, Eaton Hall, MS 3006, Kansas City, KS 66160, USABuddhadeb Dawn, Division of Cardiovascular Diseases and Cardiovascular Research Institute, University of Kansas Medical Center and Hospital, 3901 Rainbow Blvd, Rm. 1001, Eaton Hall, MS 3006, Kansas City, KS 66160, USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=4026156 Fri, 01 Oct 2010 06:58:39 +0100 4026156 http://www.medworm.com/index.php?rid=3978038&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F428013874623vv27%2F Content Type Journal ArticleDOI 10.1007/s10557-010-6258-4Authors Gaurang Prabhakar Deshpande, University of Cape Town, Cape Town, South AfricaJoy McCarthy, University of Cape Town, Cape Town, South AfricaHarshawardhan Mardikar, Spandan Heart Institute and Research Center, Nagpur, IndiaSandrine Lecour, University of Cape Town, Cape Town, South AfricaLionel Opie, University of Cape Town, Cape Town, South Africa Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3978038 Tue, 14 Sep 2010 06:00:09 +0100 3978038 http://www.medworm.com/index.php?rid=3934062&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7017r237x2u40103%2F Conclusions  Methanandamide endothelium-dependent vasorelaxation is mediated by CB1 and CB2 cannabinoid receptors. The NO- and CYP-mediated pathways contribute in a concurrent manner in this vascular effect. Stimulation of both cannabinoid receptor subtypes is indistinctly linked to NO or CYP routes to cause vasorelaxation. Content Type Journal ArticleDOI 10.1007/s10557-010-6261-9Authors Visitación López-Miranda, Dpto. Farmacología y Nutrición, Facultad Ciencias de la Salud, Universidad Rey Juan Carlos, Avda. Atenas s/n, 28922 Alcorcón, Madrid SpainM. Teresa Dannert, Dpto. Farmacología, Facultad de Medicina, Universidad Complutense de Madrid, Avda. Complutense s/n, 28040 Madrid, SpainEsperanza Herradón, Dpto. Farmacología y Nutrición, Facultad Ciencias de la ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3934062 Fri, 03 Sep 2010 17:27:23 +0100 3934062 http://www.medworm.com/index.php?rid=3930075&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn852q4p332186476%2F Conclusion  Our findings indicate that EPO+GCSF combination therapy promotes stabilization of cardiac function after acute MI. However, combination therapy does not seem to be superior to monotherapy with either EPO or GCSF. Content Type Journal ArticleDOI 10.1007/s10557-010-6263-7Authors Franca S. Angeli, Division of Cardiology, Department of Medicine, University of California, 505 Parnassus Avenue, L-523, Box 0103, San Francisco, CA 94143-0103, USANicolas Amabile, Division of Cardiology, Department of Medicine, University of California, 505 Parnassus Avenue, L-523, Box 0103, San Francisco, CA 94143-0103, USAMia Shapiro, Division of Cardiology, Department of Medicine, University of California, 505 Parnassus Avenue, L-523, Box 0103, San Francisco, CA 94143-0103, US... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3930075 Thu, 02 Sep 2010 06:49:14 +0100 3930075 http://www.medworm.com/index.php?rid=3930077&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm7g3j787j1723705%2F Conclusions  In this study involving two mouse models of AAA, simvastatin had limited efficacy in restricting aortic dilatation but substantial ability to reduce atheroma progression. Content Type Journal ArticleDOI 10.1007/s10557-010-6262-8Authors Jonathan Golledge, The Vascular Biology Unit, Department of Surgery, School of Medicine, James Cook University, Townsville, QLD Australia 4811Bradford Cullen, The Vascular Biology Unit, Department of Surgery, School of Medicine, James Cook University, Townsville, QLD Australia 4811Corey Moran, The Vascular Biology Unit, Department of Surgery, School of Medicine, James Cook University, Townsville, QLD Australia 4811Catherine Rush, The Vascular Biology Unit, Department of Surgery, School of Medicine, James Cook University, To... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3930077 Thu, 02 Sep 2010 06:49:12 +0100 3930077 http://www.medworm.com/index.php?rid=3930076&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fwx5m031354537g08%2F Content Type Journal ArticleDOI 10.1007/s10557-010-6260-xAuthors Jay N. Cohn, University of Minnesota, Minneapolis, MN USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3930076 Thu, 02 Sep 2010 06:49:12 +0100 3930076 http://www.medworm.com/index.php?rid=3878090&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F613532567p564721%2F Abstract  Antithrombotic therapy constitutes the basis of the management of acute coronary syndromes. It combines antiplatelet and anticoagulant therapy. Antiplatelet agents should combine aspirin and agents acting through the ADP pathway such as clopidogrel; newer antiplatelet agents such as prasugrel or ticagrelor have superior anti-ischemic efficacy, compared with clopidogrel. Intravenous glycoprotein IIb/IIIa inhibitors may be used in selected patients at high risk undergoing percutaneous coronary interventions. Unfractionated heparin constitutes the reference anticoagulant treatment. Enoxaparin provides slightly better anti-ischemic efficacy. Newer agents, such as bivalirudin or fondaparinux, reduce bleeding complications, with no improvement in anti-ischemic efficacy. ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3878090 Tue, 17 Aug 2010 05:55:39 +0100 3878090 http://www.medworm.com/index.php?rid=3832479&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F703276313703lr56%2F Discussion  For prevention of acute myocardial infarction, it is widely accepted to treat high risk patients with aspirin and/or statins. On the other hand, several medications such as angiotensin converting enzyme inhibitors, aldosterone receptor antagonists and beta blockers have been used for the prevention of post-infarction heart failure in patients who have suffered from an acute myocardial infarction. However, at present we do not have an adjunctive drug therapy to reduce infarct size in the acute phase in patients with myocardial infarction. Recently, the J-WIND trials suggested that an infusion of human atrial natriuretic peptide in the acute phase and oral administration of nicorandil in the chronic phase of infarction result in a better outcome in patients with a... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3832479 Fri, 06 Aug 2010 07:47:40 +0100 3832479 http://www.medworm.com/index.php?rid=3832480&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn531362m754v34j6%2F Abstract  The endothelium mediates relaxations (dilatations) of the underlying vascular smooth muscle cells. The endothelium-dependent relaxations are due to the release of non-prostanoid vasodilator substances. The best characterized endothelium-derived relaxing factor (EDRF) is nitric oxide (NO). The endothelial cells also release substances (endothelium-derived hyperpolarizing factor, EDHF) that cause hyperpolarization of the cell membrane of the underlying vascular smooth muscle. The release of EDRF from the endothelium can be mediated by both pertussis toxin-sensitive Gi (alpha2-adrenergic activation, serotonin, thrombin) and insensitive Gq (adenosine diphosphate, bradykinin) coupling proteins. The ability of the endothelial cell to release relaxing factors can be upreg... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3832480 Fri, 06 Aug 2010 07:47:39 +0100 3832480 http://www.medworm.com/index.php?rid=3809882&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv71p7x5h035x5424%2F Abstract  Aldosterone is present and active all along the cardiovascular continuum. Excessive tissue production occurs in cardiovascular diseases including myocardial infarction (MI) and heart failure, resulting in a multitude of adverse effects in the cardiovascular system necessitating pharmacologic blockade of this neurohormone. Both human and animal studies have consistently proven the beneficial effects of antialdosteronics in the improvement of: 1) endothelial function, 2) modulation of inflammatory mechanisms between blood and the vascular wall and 3) reduction of tissue proliferation and cardiovascular remodeling leading to different severities of cardiovascular damage. These basic mechanisms of anti-aldosterone therapy strongly support the promising data observed i... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3809882 Fri, 30 Jul 2010 17:02:56 +0100 3809882 http://www.medworm.com/index.php?rid=3809881&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F53286hlk813704l7%2F Conclusion  Overall, there was no noticeable difference between resveratrol treatment groups on the recovery from diabetes. Our results indicate that resveratrol alleviates type 1 diabetes-induced vasculopathy by decreasing vascular oxidative stress and thereby increasing the bioavailability of nitric oxide without changing metabolic abnormalities. Content Type Journal ArticleDOI 10.1007/s10557-010-6255-7Authors Fatma Akar, Gazi University Department of Pharmacology, Faculty of Pharmacy Etiler Ankara TurkeyM. Bilgehan Pektas, Gazi University Department of Pharmacology, Faculty of Pharmacy Etiler Ankara TurkeyCan Tufan, Gazi University Department of Pharmacology, Faculty of Pharmacy Etiler Ankara TurkeySelen Soylemez, Gazi University Department of Pharmacology, Facult... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3809881 Fri, 30 Jul 2010 17:02:56 +0100 3809881 http://www.medworm.com/index.php?rid=3791854&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv651k1603086m15n%2F This article reviews drugs that alleviate the symptoms of chronic angina with emphasis on several novel pharmacological agents. Content Type Journal ArticleDOI 10.1007/s10557-010-6254-8Authors Danny Dvir, Tel Aviv University Cardiology Department, Rabin Medical Center, Petach Tikva, Sackler Faculty of Medicine 49100 Tel Aviv IsraelAlexander Battler, Tel Aviv University Cardiology Department, Rabin Medical Center, Petach Tikva, Sackler Faculty of Medicine 49100 Tel Aviv Israel Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3791854 Sat, 24 Jul 2010 13:47:51 +0100 3791854 http://www.medworm.com/index.php?rid=3785062&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5148454r5652r453%2F Conclusions  Short-term treatment with dronedarone did not affect exercise capacity and did not decrease LVEF in patients with severe LV dysfunction and compensated HF. Content Type Journal ArticleDOI 10.1007/s10557-010-6251-yAuthors T. Barry Levine, Michigan Institute for Heart Failure and Transplant Care Farmington Hills MI USAThomas Giles, Louisiana State University School of Medicine New Orleans LA USADavid Radzik, sanofi-aventis Paris FranceJalal K. Ghali, Louisiana State University School of Medicine Shreveport LA USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3785062 Fri, 23 Jul 2010 12:17:58 +0100 3785062 http://www.medworm.com/index.php?rid=3777900&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy04646x303113511%2F Abstract  Ischemic heart failure is one of the leading causes of death in the western countries and it is a critical issue to overcome ischemic heart diseases for the human health care worldwide. There are several aspects of ischemic heart failure that we need to seriously consider for the conquest of cardiovascular death. First of all, we need to know either causes or pathophysiology of the onset of coronary artery disease, the ischemia/reperfusion injury and post-infarction cardiac remodeling. Secondly, we need to find the potential seeds for the molecular, pharmacological, biomedical or engineering treatment to prevent or attenuate ischemic heart diseases. Thirdly, we need to accelerate translational research and to create the network of clinical trials to grow the novel... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3777900 Mon, 19 Jul 2010 17:50:29 +0100 3777900 http://www.medworm.com/index.php?rid=3773707&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F342w6g48537n6513%2F Conclusions  During acute myocardial ischemia, DIP alone or with low-dose ASA limits IS and does not attenuate the IS-limiting effect of SIM as high-dose ASA. Content Type Journal ArticleDOI 10.1007/s10557-010-6252-xAuthors Yumei Ye, The University of Texas Medical Branch Department of Biochemistry and Molecular Biology Galveston TX USABo Long, The University of Texas Medical Branch Department of Biochemistry and Molecular Biology Galveston TX USAJinqiao Qian, The University of Texas Medical Branch Department of Biochemistry and Molecular Biology Galveston TX USAJose R. Perez-Polo, The University of Texas Medical Branch Department of Biochemistry and Molecular Biology Galveston TX USAYochai Birnbaum, The University of Texas Medical Branch Department of Biochemistry an... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3773707 Fri, 16 Jul 2010 18:41:09 +0100 3773707 http://www.medworm.com/index.php?rid=3773708&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa47304x59x251555%2F Conclusions  Measurement of arterial stiffness will not only be helpful in the detection of early vascular disease but also as a tool in the selection and follow-up monitoring of therapeutic strategies aimed at preventing or delaying progression of vascular disease. Content Type Journal ArticleDOI 10.1007/s10557-010-6250-zAuthors Daniel A. Duprez, University of Minnesota Cardiovascular Division, Medical School VCRC Room 270, 420 Delaware St SE, MMC 508 Minneapolis MN 55455 USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3773708 Wed, 14 Jul 2010 22:48:42 +0100 3773708 http://www.medworm.com/index.php?rid=3741607&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe3511h74v5387u7u%2F Conclusions  In patients with mixed hyperlipidemia, n-3-PSE treatment may offer a safe and effective therapy for triglyceride level reduction while avoiding the typical increase in LDL-C levels associated with n-3 fatty acid treatment. The observed reduction in blood pressure and inflammation markers warrants further evaluation. The positive effect of n-3-PSE treatment was preserved at the end of the follow up phase. Content Type Journal ArticleDOI 10.1007/s10557-010-6249-5Authors Rafael Bitzur, Sheba Medical Center The Bert W. Strassburger Lipid Center Tel Hashomer IsraelHofit Cohen, Sheba Medical Center The Bert W. Strassburger Lipid Center Tel Hashomer IsraelTzafra Cohen, Enzymotec Ltd R&D Department Migdal HaEmeq IsraelTali W. Dror, Enzymotec Ltd R&D Department ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3741607 Thu, 08 Jul 2010 16:19:02 +0100 3741607 http://www.medworm.com/index.php?rid=3727692&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F764uk726466g6883%2F Conclusion  Further studies are required to address the uncertainty that exists on the most appropriate duration of therapy as well as the effectiveness and safety of combination pharmacotherapy. Post-marketing surveillance continues to play an important role in monitoring the adverse effects events associated with these therapies. Content Type Journal ArticleDOI 10.1007/s10557-010-6246-8Authors John J. McNeil, Monash University Department of Epidemiology & Preventive Medicine, School of Public Health & Preventive Medicine, Alfred Hospital Melbourne Victoria 3004 AustraliaLoretta Piccenna, Monash University Department of Epidemiology & Preventive Medicine, School of Public Health & Preventive Medicine, Alfred Hospital Melbourne Victoria 3004 AustraliaLisa L. Ioannide... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3727692 Sun, 04 Jul 2010 22:46:38 +0100 3727692 http://www.medworm.com/index.php?rid=3727693&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fkmr2347185q12244%2F Content Type Journal ArticleDOI 10.1007/s10557-010-6247-7Authors Willem J. Remme, Sticares Cardiovascular Research Institute P.O. Box 882 3160 AB Rhoon The Netherlands Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3727693 Fri, 02 Jul 2010 19:45:24 +0100 3727693 http://www.medworm.com/index.php?rid=3715533&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh05883195011p710%2F Conclusions  Hypothesizing that dual antiplatelet therapy would provide benefit across the broad spectrum of atherothrombotic disease was plausible. In retrospect, it is apparent that by combining such a heterogeneous population, CHARISMA failed to show a clear treatment effect for DAPT and potentially masked important benefits in specific populations. Given the inherent clinical and biological variability among patients and disease states, difficult-to-interpret clinical data should not be dismissed. The current challenge is identifying clinically useful data from CHARISMA to determine the role of DAPT in contemporary clinical practice. Content Type Journal ArticleDOI 10.1007/s10557-010-6245-9Authors William E. Boden, University at Buffalo School of Medicine and ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3715533 Wed, 30 Jun 2010 15:21:59 +0100 3715533 http://www.medworm.com/index.php?rid=3715534&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fkq720v07u378j567%2F Abstract  Reperfusion therapy is the primary treatment of acute myocardial infarction and must be applied as soon as possible to limit the ischemic insult. Unfortunately, reperfusion is responsible for additional myocardial damage likely involving opening of the mitochondrial permeability transition pore. Ischemic postconditioning is a powerful intervention that dramatically reduces lethal reperfusion injury. Several clinical studies using angioplasty postconditioning now support its protective effects in patients with an acute myocardial infarction. Alternatively, pharmacological postconditioning could afford comparable protection and be applied to a much larger number of patients. Indeed, the mitochondrial permeability transition pore inhibitor cyclosporine A has been sho... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3715534 Tue, 29 Jun 2010 16:33:25 +0100 3715534 http://www.medworm.com/index.php?rid=3708016&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F604x575540228951%2F Conclusion  A short course of Exendin-4 in the neonatal period leads to protection from ischemic injury and a preconditioned mitochondrial phenotype in the adult rat. Content Type Journal ArticleDOI 10.1007/s10557-010-6242-zAuthors Suzanne B. Brown, Hospital of the University of Pennsylvania Philadelphia PA USAJoseph R. Libonati, University of Pennsylvania School of Nursing Philadelphia PA USAMary A. Selak, Children’s Hospital of Philadelphia Philadelphia PA USARichard P. Shannon, Hospital of the University of Pennsylvania Philadelphia PA USARebecca A. Simmons, Hospital of the University of Pennsylvania Philadelphia PA USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3708016 Sat, 26 Jun 2010 16:21:49 +0100 3708016 http://www.medworm.com/index.php?rid=3700429&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F33742j8225v16n43%2F We report our experience in this context with perindopril. Content Type Journal ArticleDOI 10.1007/s10557-010-6244-xAuthors Roberto Ferrari, Arcispedale S. Anna Hospital Chair of Cardiology, University of Ferrara, Cardiovascular Institute C.rso Giovecca 203 Ferrara 44100 ItalyGabriele Guardigli, University Hospital of Ferrara Ferrara ItalyClaudio Ceconi, Arcispedale S. Anna Hospital Chair of Cardiology, University of Ferrara, Cardiovascular Institute C.rso Giovecca 203 Ferrara 44100 Italy Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3700429 Fri, 25 Jun 2010 16:54:15 +0100 3700429 http://www.medworm.com/index.php?rid=3667744&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ftj3p5v8347087157%2F This article reviews the existing evidence underpinning current therapeutic strategies aimed at achieving atherosclerotic plaque regression. In this review we also discuss imaging modalities for the assessment of plaque regression, predictors of regression and whether plaque regression is associated with a survival benefit. Content Type Journal ArticleDOI 10.1007/s10557-010-6241-0Authors Nesan Shanmugam, St George’s University of London Division of Cardiac and Vascular Sciences Cranmer Terrace London SW17 0RE UKAna Román-Rego, St George’s University of London Division of Cardiac and Vascular Sciences Cranmer Terrace London SW17 0RE UKPeter Ong, St George’s University of London Division of Cardiac and Vascular Sciences Cranmer Terrace London SW17 0RE UKJuan Carlos Kaski, St... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3667744 Mon, 14 Jun 2010 14:06:54 +0100 3667744 http://www.medworm.com/index.php?rid=3653542&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh640200p24034034%2F Conclusions  Sufficient rapamycin can inhibit the growth of C. pneumoniae effectively, but it should be applied at the early stage of the chlamydial infections. Rapamycin eluting-stents can induce a high enough local concentration of rapamycin. This provides a possibility for us to suppose that the beneficial effect of rapamycin in preventing in-stent restenosis might partly be explained by its inhibitory effects on the growth of C. pneumoniae. Content Type Journal ArticleDOI 10.1007/s10557-010-6238-8Authors Ying Yan, University of Oulu Department of Medical Microbiology PO BOX 5000 90014 Oulu FinlandSylvi Silvennoinen-Kassinen, University of Oulu Department of Medical Microbiology PO BOX 5000 90014 Oulu FinlandMaija Leinonen, National Institute for Health and Welfar... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3653542 Wed, 09 Jun 2010 09:13:45 +0100 3653542 http://www.medworm.com/index.php?rid=3653543&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fggn56q8145160643%2F This article will primarily discuss the existing literature regarding protection of Postcon on the heart, but there is a potential for future research into other organ systems to identify beneficial effects of Postcon on tissue reperfusion injury, particularly in patients undergoing surgical revascularization. Content Type Journal ArticleDOI 10.1007/s10557-010-6240-1Authors Zhi-Qing Zhao, Mercer University School of Medicine Cardiovascular Research Laboratory Savannah GA USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3653543 Wed, 09 Jun 2010 09:13:43 +0100 3653543 http://www.medworm.com/index.php?rid=3626902&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx0487402418165q8%2F Abstract  To date, all major clinical trials for anemia correction using erythrocyte stimulating agents (ESAs) failed to show improved outcomes for cardiovascular disease (CVD), stroke, and vascular thrombosis. Even moderate elevations in hemoglobin (e.g., to 13 g/dL) using erythropoietin have been associated with significantly increased risk of thrombotic cardiovascular events and heart failure. This review presents a biophysical rationale for increased risk of CVD among certain patients treated with ESAs and suggests a risk management approach based on blood viscosity. Whole blood viscosity is a key determinant of the work of the heart, and elevated blood viscosity appears to be both a strong predictor of cardiovascular disease and an important pathophysiological fac... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3626902 Tue, 01 Jun 2010 06:05:19 +0100 3626902 http://www.medworm.com/index.php?rid=3611037&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq152125q24743538%2F Abstract  A series of brief ischemia/reperfusion cycles (termed ischemic preconditioning, IPC) limits myocardial injury produced by a subsequent prolonged period of coronary artery occlusion and reperfusion. Over the last 2 decades our understanding of IPC’s mechanism has increased exponentially. Hearts exposed to IPC have a better metabolic and ionic status during prolonged ischemia compared to naïve hearts. However, this difference is not thought to be the main mechanism by which IPC protects against infarction. Signaling pathways that are activated by IPC distinguish IPC hearts from naïve hearts. During the trigger phase of IPC, adenosine, bradykinin and opioid receptors are occupied. Although these three receptors trigger signaling through divergent pathways, the si... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3611037 Thu, 27 May 2010 11:01:04 +0100 3611037 http://www.medworm.com/index.php?rid=3600749&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw0116g41052677j2%2F Abstract  A standard ischemic preconditioning (IPC) stimulus of one or more brief episodes of non-lethal myocardial ischemia and reperfusion elicits a bi-phasic pattern of cardioprotection. The first phase manifests almost immediately following the IPC stimulus and lasts for 1–2 h, after which its effect disappears (termed classical or early IPC). The second phase of cardioprotection appears 12–24 h later and lasts for 48–72 h (termed the Second Window of Protection [SWOP] or delayed or late IPC). The cardioprotection conferred by delayed IPC is robust and ubiquitous but is not as powerful as early IPC. Although there are some similarities in the mechanisms underlying early and delayed IPC, one of the major distinctions between the two is the latter’s ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3600749 Sat, 22 May 2010 16:49:37 +0100 3600749 http://www.medworm.com/index.php?rid=3582764&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl8t6132p7hmg206u%2F Conclusions  High dose ARB therapy or combination therapies with ACE inhibitors and ARBs have shown beneficial effects on surrogate markers of chronic kidney disease. Early data based on urinary protein excretion rates as a surrogate marker for renal function suggest a possibly novel role for aliskiren alone or in combination with ARBs in chronic kidney disease. Content Type Journal ArticleDOI 10.1007/s10557-010-6232-1Authors Christian W. Mende, University of California at San Diego Department of Medicine 6950 Fairway Road La Jolla CA 92037 USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3582764 Wed, 19 May 2010 17:59:51 +0100 3582764 http://www.medworm.com/index.php?rid=3582763&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv610246v5k64255t%2F Abstract  The mitochondrion is a powerhouse of the cell, a platform of cell signaling and decision-maker of cell death, including death by ischemia/reperfusion. Ischemia shuts off ATP production by mitochondria, and cell viability is compromised by energy deficiency and build-up of cytotoxic metabolites during ischemia. Furthermore, the mitochondrial permeability transition pore (mPTP) is primed by ischemia to open upon reperfusion, leading to reperfusion-induced cell necrosis. mPTP opening can be suppressed by ischemic preconditioning (IPC) and other interventions that induce phosphorylation of GSK-3β. Activation of the mitochondrial ATP-sensitive K+ channel (mKATP channel) is an important signaling step in a trigger phase of IPC, which ultimately enhances GSK-3β phosphor... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3582763 Wed, 19 May 2010 17:59:51 +0100 3582763 http://www.medworm.com/index.php?rid=3582765&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4161h6054180p532%2F Conclusions  The PERFORM Vascular Project will investigate terutroban’s effect on vascular structure and function in patients with a history of ischemic stroke or TIAs. Content Type Journal ArticleDOI 10.1007/s10557-010-6231-2Authors Michael G. Hennerici, University of Heidelberg Department of Neurology Mannheim GermanyMichiel L. Bots, University Medical Center Utrecht Julius Center for Health Sciences and Primary Care Utrecht The NetherlandsIan Ford, Robertson Centre for Biostatistics Glasgow UKStéphane Laurent, Hôpital Européen Georges Pompidou Department of Pharmacology and INSERM U970 Paris FrancePierre Jean Touboul, Hôpital Bichat Department of Neurology and Stroke Center Paris France Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3582765 Wed, 19 May 2010 17:59:50 +0100 3582765 http://www.medworm.com/index.php?rid=3582766&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fbn622q6368155436%2F Conclusion  The results of the present study do not support the assumption that hydralazine could be viewed as a “NO enhancer”; there is no evidence of attenuation of NO resistance by hydralazine treatment. Content Type Journal ArticleDOI 10.1007/s10557-010-6233-0Authors Yuliy Y. Chirkov, Cardiology Unit, Vascular Disease and Therapeutics Research Group, Basil Hetzel Institute, The Queen Elizabeth Hospital, School of Medicine, The University of Adelaide Adelaide AustraliaMichele De Sciscio, Cardiology Unit, Vascular Disease and Therapeutics Research Group, Basil Hetzel Institute, The Queen Elizabeth Hospital, School of Medicine, The University of Adelaide Adelaide AustraliaAaron L. Sverdlov, Cardiology Unit, Vascular Disease and Therapeutics Research Group, Basil ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3582766 Wed, 19 May 2010 17:59:48 +0100 3582766 http://www.medworm.com/index.php?rid=3553605&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv701j52177718856%2F Content Type Journal ArticleDOI 10.1007/s10557-010-6230-3Authors Jay N. Cohn, University of Minnesota Medical School Department of Medicine, Cardiovascular Division Mayo Mail Code 508, 420 Delaware Street Southeast Minneapolis MN 55455 USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3553605 Sat, 08 May 2010 10:14:03 +0100 3553605 http://www.medworm.com/index.php?rid=3491663&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0628r4342583nj25%2F Conclusion  We found that upregulation of HIF-1 could protect isolated cardiac myocytes against nitrate tolerance through a cyclic GMP protein kinase-independent mechanism and through a kinase-dependent mechanism in stunning. Content Type Journal ArticleDOI 10.1007/s10557-010-6229-9Authors Tao Tan, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School Heart and Brain Circulation Laboratory, Department of Physiology and Biophysics 675 Hoes Lane West Piscataway NJ 08854 USAHarvey R. Weiss, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School Heart and Brain Circulation Laboratory, Department of Physiology and Biophysics 675 Hoes Lane West Piscataway NJ 08854 USA Journal Cardiovascular Drugs and Th... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3491663 Tue, 20 Apr 2010 11:03:32 +0100 3491663 http://www.medworm.com/index.php?rid=3477033&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk54n46624555681r%2F Conclusions  The published evidence supports the updates to the guidelines. Updated guidelines still have knowledge gaps which require the application of clinical discretion by the cardiologist. Content Type Journal ArticleDOI 10.1007/s10557-010-6226-zAuthors José G. Díez, Texas Heart Institute, Baylor College of Medicine St. Luke’s Episcopal Hospital 1709 Dryden Rd., BCM 620, Suite 9.40 Houston TX 77030 USAJames M. Wilson, Texas Heart Institute, Baylor College of Medicine St. Luke’s Episcopal Hospital 1709 Dryden Rd., BCM 620, Suite 9.40 Houston TX 77030 USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3477033 Tue, 13 Apr 2010 18:18:11 +0100 3477033 http://www.medworm.com/index.php?rid=3469164&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa42m624507240j60%2F Conclusions  Patient-tailored statin therapy according to an individual’s risk category and LDL-C levels was safe and effective with a quick achievement of LDL-C target in Korean dyslipidemic patients. Content Type Journal ArticleDOI 10.1007/s10557-010-6225-0Authors Cheol Whan Lee, Asan Medical Center Seoul South KoreaSang-Hong Baek, The Catholic University of Korea Division of Cardiology, Seoul St. Mary’s Hospital 505 Banpo-dong, Seocho-gu Seoul 137-701 South KoreaTaek-Jong Hong, Pusan National University Hospital Busan South KoreaYoung-Jin Choi, Hallym University Sacred Heart Hospital Anyang Gyeonggi South KoreaYoung-Jo Kim, Yeungnam University Hospital Daegu South KoreaTae-Hoon Ahn, Gachon University Gil Medical Center Incheon South KoreaSang-Hyun Ihm, The Cath... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3469164 Sat, 10 Apr 2010 07:49:00 +0100 3469164 http://www.medworm.com/index.php?rid=3469165&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk743322103823715%2F Conclusions  TAK-491 and PIO independently limited myocardial IS in a dose-dependent fashion; and the effects were additive. The mechanism of protection and the role of TAK-491 in this clinical setting should be further investigated. Content Type Journal ArticleDOI 10.1007/s10557-010-6227-yAuthors Yumei Ye, The University of Texas Medical Branch The Department of Biochemistry and Molecular Biology Galveston TX USAKyle T. Keyes, The University of Texas Medical Branch The Department of Biochemistry and Molecular Biology Galveston TX USAChong F. Zhang, The University of Texas Medical Branch The Department of Biochemistry and Molecular Biology Galveston TX USAJose R. Perez-Polo, The University of Texas Medical Branch The Department of Biochemistry and Molecular Biology Ga... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3469165 Thu, 08 Apr 2010 18:02:01 +0100 3469165 http://www.medworm.com/index.php?rid=3426320&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F46g68g3123k51275%2F Conclusion  Beta1-AR Arg389Gly and beta2-AR Arg16Gly SNPs are not related to the response to carvedilol therapy. In contrast, the Gln27Glu SNP is a determinant of the LVEF response to this agent in patients with chronic HF. Content Type Journal ArticleDOI 10.1007/s10557-010-6220-5Authors Marco Metra, University of Brescia Institute of Cardiology, Department of Experimental and Applied Medicine Brescia ItalyLoredana Covolo, University of Brescia Institute of Hygiene, Epidemiology and Public Health, Department of Experimental and Applied Medicine Brescia ItalyNatalia Pezzali, University of Brescia Institute of Cardiology, Department of Experimental and Applied Medicine Brescia ItalyValerio Zacà, University of Brescia Institute of Cardiology, Department of Experimental ... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3426320 Tue, 30 Mar 2010 05:46:30 +0100 3426320 http://www.medworm.com/index.php?rid=3426319&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F47h3841x2758j70v%2F Conclusions  The PACIFIC Registry will give insights as to the Japanese epidemiology of ACS: recurrence of atherothrombotic events in the same or other vascular territories. Content Type Journal ArticleDOI 10.1007/s10557-010-6223-2Authors Katsumi Miyauchi, Juntendo University Department of Cardiovascular Medicine, School of Medicine 2-1-1 Hongo Bunkyo-ku Tokyo 113-8421 JapanYoshihiro Morino, Tokai University Department of Cardiology, School of Medicine Isehara JapanKengo Tsukahara, Yokohama City University Medical Center Division of cardiology Yokohama JapanHideki Origasa, University of Toyama Division of Biostatistics and Clinical Epidemiology Toyama JapanHiroyuki Daida, Juntendo University Department of Cardiovascular Medicine, School of Medicine 2-1-1 Hongo Bunkyo-... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3426319 Tue, 30 Mar 2010 05:46:30 +0100 3426319 http://www.medworm.com/index.php?rid=3367109&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv16886p8t1382613%2F Conclusions  Our data demonstrated that, in our ex vivo model of myocardial ischaemia-reperfusion injury, AMPK activation in early reperfusion is associated with a reduction in infarct size. Content Type Journal ArticleDOI 10.1007/s10557-010-6222-3Authors Marta A. Paiva, University College London Hospitals and Medical School The Hatter Cardiovascular Institute 67 Chenies Mews London WC1E 6HX UKLino M. Gonçalves, Coimbra University Hospital and Coimbra Medical School Basic Research in Cardiology Unit, IBILI Coimbra PortugalLuis A. Providência, Coimbra University Hospital and Coimbra Medical School Basic Research in Cardiology Unit, IBILI Coimbra PortugalSean M. Davidson, University College London Hospitals and Medical School The Hatter Cardiovascular Institute 67 Che... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3367109 Sun, 14 Mar 2010 11:27:56 +0100 3367109 http://www.medworm.com/index.php?rid=3367110&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu21t4tt30182j7g6%2F Conclusion  Lowering blood pressure, either with eprosartan or other anti-hypertensives in hypertensive patients with diastolic dysfunction did not change diastolic function after 6 months of treatment, but was associated with a decrease of NT-proBNP. Content Type Journal ArticleDOI 10.1007/s10557-010-6221-4Authors Adriaan A. Voors, University Medical Centre Groningen Department of Cardiology PO Box 30.001 9700 RB Groningen The NetherlandsRuud M. van de Wal, St. Antonius Hospital Nieuwegein Nieuwegein The NetherlandsJasper W. L Hartog, University Medical Centre Groningen Department of Cardiology PO Box 30.001 9700 RB Groningen The NetherlandsRichard G. Vijn, Refaja Hospital Stadskanaal Stadskanaal The NetherlandsYoran M. Hummel, University Medical Centre Groninge... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3367110 Sun, 14 Mar 2010 11:27:55 +0100 3367110 http://www.medworm.com/index.php?rid=3360420&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgnr7304p37515785%2F Conclusion  A single high loading dose of rosuvastatin reduces the incidence of peri-procedural myocardial necrosis and infarction effectively. Content Type Journal ArticleDOI 10.1007/s10557-010-6224-1Authors Serkan Cay, Yuksek Ihtisas Heart-Education and Research Hospital Department of Cardiology Ankara TurkeyGoksel Cagirci, Ministry of Health Dışkapı Yıldırım Beyazıt Research and Educational Hospital Department of Cardiology Ankara TurkeyNihat Sen, Mustafa Kemal University, Faculty of Medicine Department of Cardiology Hatay TurkeyYucel Balbay, Yuksek Ihtisas Heart-Education and Research Hospital Department of Cardiology Ankara TurkeyTahir Durmaz, Ataturk Education and Research Hospital Department of Cardiology Ankara TurkeySinan Aydogdu, Yuksek Ihtisas Heart-Edu... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3360420 Thu, 11 Mar 2010 02:45:03 +0100 3360420 http://www.medworm.com/index.php?rid=3312807&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fru51066276210108%2F Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s10557-010-6219-yAuthors Andreas Skyschally, Institut für Pathophysiologie, Universitätsklinikum Essen Hufelandstraße 55 45122 Essen GermanyRainer Schulz, Institut für Pathophysiologie, Universitätsklinikum Essen Hufelandstraße 55 45122 Essen GermanyGerd Heusch, Institut für Pathophysiologie, Universitätsklinikum Essen Hufelandstraße 55 45122 Essen Germany Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3312807 Thu, 25 Feb 2010 06:56:10 +0100 3312807 http://www.medworm.com/index.php?rid=3285200&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr15j21368332n0r3%2F Content Type Journal ArticleCategory ErratumDOI 10.1007/s10557-010-6218-zAuthors Huige Li, Johannes Gutenberg University Department of Pharmacology Obere Zahlbacher Strasse 67 55131 Mainz GermanyUlrich Förstermann, Johannes Gutenberg University Department of Pharmacology Obere Zahlbacher Strasse 67 55131 Mainz Germany Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3285200 Wed, 17 Feb 2010 18:31:19 +0100 3285200 http://www.medworm.com/index.php?rid=3281050&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0794m3542l123520%2F Conclusions  Such effects of intracoronary levosimendan bolus administration during regional myocardial ischemia indicate the occurrence of cardio-protection by modulation of programmed form of cell death. Content Type Journal ArticleDOI 10.1007/s10557-010-6217-0Authors Elena Grossini, University of East Piedmont “A. Avogadro” Department of Clinical and Experimental Medicine, Physiology Section Via Solaroli 17 28100 Novara ItalyPhilippe Primo Caimmi, Ospedale Maggiore della Carità Department of Cardiac Surgery C.so Mazzini 18 28100 Novara ItalyFrancesca Platini, University of East Piedmont “A. Avogadro” Department of Food, Chemical, Pharmaceutical and Pharmacological Sciences (DISCAFF) Novara ItalyClaudio Molinari, University of East Piedmont “A. Avogadro�... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3281050 Tue, 16 Feb 2010 18:08:22 +0100 3281050 http://www.medworm.com/index.php?rid=3232817&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl80741k02q0867vu%2F Conclusions  These data clearly show that G-CSF treatment was unable to restore cardiac function impaired by myocardial infarction either with classical approach or long term low dose administration. Content Type Journal ArticleDOI 10.1007/s10557-010-6215-2Authors Ruy A. N. Louzada, UFRJ Laboratório de Cardiologia Celular e Molecular do Instituto de Biofísica Carlos Chagas Filho Rio de Janeiro CEP 21941-902 BrasilPatricia F. Oliveira, UFRJ Laboratório de Cardiologia Celular e Molecular do Instituto de Biofísica Carlos Chagas Filho Rio de Janeiro CEP 21941-902 BrasilJoao Paulo A. Cavalcanti-de-Albuquerque, EEFD—UFRJ Laboratório de Biologia do Exercício do Departamento de Biociências e Atividade Física Rio de Janeiro CEP 21941-599 BrasilLeandro Cunha-Carvalho, E... Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3232817 Mon, 01 Feb 2010 18:05:47 +0100 3232817 http://www.medworm.com/index.php?rid=3228661&cid=s_33443_7_f&fid=33443&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx8646un371377l8t%2F Content Type Journal ArticleDOI 10.1007/s10557-010-6216-1Authors Jay N. Cohn, University of Minnesota Medical School Cardiovascular Division, Mayo Mail Code 508 420 Delaware Street Southeast Minneapolis MN 55455 USA Journal Cardiovascular Drugs and TherapyOnline ISSN 1573-7241Print ISSN 0920-3206 (Source: Cardiovascular Drugs and Therapy) Cardiovascular Drugs and Therapy journals http://www.medworm.com/rss/comments.php?id=3228661 Fri, 29 Jan 2010 12:18:32 +0100 3228661